Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 23121. Отображено 100.
05-01-2012 дата публикации

Chroman derivatives, medicaments and use in therapy

Номер: US20120004296A1
Автор: Alan Husband, Andrew Heaton
Принадлежит: Marshall Edwards Inc

Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Подробнее
Номер записи: 1
12-01-2012 дата публикации

Drug Delivery System for Use in the Treatment of Vascular and Vessel-Related Pathologies

Номер: US20120010557A1
Автор: Michal Heger
Принадлежит: ACADEMISCH MEDISCH CENTRUM

The present invention relates to a drug delivery system for use in the treatment of vascular and vessel-related pathologies, comprising a drug delivery platform that comprises at least one compound capable of exerting an effect on the formation and/or maintenance of a thrombus in the vessel to be treated. The platform is preferably formed by liposomes that are sterically stabilized by grafting of poly(ethylene glycol) onto the liposome surface. The liposomes may further comprise photosensitizers and targeting molecules. The liposomes may be thermosensitive. The compound is suitably tranexamic acid. The drug delivery system is preferably used for the treatment of port wine stains.

Подробнее
Номер записи: 2
12-01-2012 дата публикации

Orthopedic cement and use of same in radiation therapy

Номер: US20120010601A1
Автор: George Ding, Joseph Cheng, Scott D. Simon
Принадлежит: VANDERBILT UNIVERSITY

A method of treating diseased tissue in a patient, the diseased tissue being proximate a hardened previously implanted bone cement including relatively high atomic number elements in a patient. The method includes generating a photon beam and directing the generated photon beam into the patient in a direction such that at least a portion of the photon beam impinges on the hardened bone cement and generates Compton interaction knock-out electrons from the high atomic number elements included in the hardened bone cement as a result of interaction of the at least a portion of the photon beam with the bone cement, wherein the direction of the photon beam is such that the at least a portion of the photon beam impinges on the hardened bone cement so that at least some of the Compton interaction knock-out electrons impinge upon the diseased tissue.

Подробнее
Номер записи: 3
02-02-2012 дата публикации

Contrast agent for photoacoustic imaging and photoacoustic imaging method using the same

Номер: US20120027679A1
Автор: Fumio Yamauchi, Kengo Kanazaki, Masato Minami, Mayuko Kishi, Sachiko Inoue, Satoshi Ogawa, Tatsuki Fukui
Принадлежит: Canon Inc

It is intended to provide a novel contrast agent for photoacoustic imaging that is highly capable of binding to a target molecule and generates high photoacoustic signals. The present invention provides a contrast agent for photoacoustic imaging represented by Formula 1: MNP−((L) l −(P) m ) n   (Formula 1) (wherein MNP represents a particle containing an iron oxide particle; L represents a linker molecule; P represents a ligand molecule; l represents 0 or 1; and m and n represent an integer of 1 or larger), the contrast agent for photoacoustic imaging including: a particle containing an iron oxide particle that absorbs light in a near-infrared region; and at least one or more ligand molecule(s) immobilized on the particle containing an iron oxide particle, wherein the immobilization density of the ligand molecule is equal to or higher than the cell surface density of a target molecule.

Подробнее
Номер записи: 4
09-02-2012 дата публикации

Artificial cells

Номер: US20120034155A1
Автор: Elizabeth A. Sweeney, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Wayne R. Kindsvogel
Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее
Номер записи: 5
09-02-2012 дата публикации

Artificial cells

Номер: US20120034157A1
Автор: Elizabeth A. Sweeney, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Wayne A. Kindsvogel
Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее
Номер записи: 6
09-02-2012 дата публикации

Pharmaceutical composition for treating cancer comprising chlorin e6-folic acid conjugate compound and chitosan

Номер: US20120035180A1
Автор: Eun Hee Lee, Hyo Jun Kim, Kye Shin Park
Принадлежит: Diatech Korea Co Ltd

The present invention relates to a pharmaceutical composition for the treatment of cancer comprising a chlorin e6-folic acid conjugate compound and chitosan, and more particularly, to a pharmaceutical composition for photodynamic therapy of solid tumors comprising the novel chlorin e6-folic acid conjugate compound or a pharmaceutically acceptable salt thereof and chitosan, in which the novel compound is prepared by linking chlorin e6 to folic acid, and effectively produces singlet oxygen in various media and has much better tumor selectivity than the known porphyrin-based photosensitizers, thereby being used effectively in photodynamic treatment for malignant tumors.

Подробнее
Номер записи: 7
23-02-2012 дата публикации

Combination therapy with parp inhibitors

Номер: US20120045524A1
Автор: Thomas D. Penning, Vincent L. Giranda, Wolfgang Wernet
Принадлежит: ABBOTT LABORATORIES

The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.

Подробнее
Номер записи: 8
19-04-2012 дата публикации

Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof

Номер: US20120093918A1
Автор: Gabriel Charest, Leon Sanche
Принадлежит: SOCPRA Sciences Sante et Humaines sec

A combination of an anti-cancer agent and a metal radiosensitizer potentiates the radiotherapy of cancer. Said anti-cancer agent is preferably cisplatin while the metal radiosensitizer is preferably gold nanoparticles. Both the anti-cancer agent and the metal radiosensitizer bind to DNA and potentiate the radiotherapy of cancer by synergistically increases the amount of double strand breaks induced by the radiation. The anti-cancer agent and the metal radiosensitizer may be encapsulated in liposomes.

Подробнее
Номер записи: 9
19-04-2012 дата публикации

Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof

Номер: US20120094900A1
Автор: Emma Ito, Fei-Fei Liu, Inki Kim
Принадлежит: UNIVERSITY HEALTH NETWORK

There is provided herein methods, compounds and methods for identifying compounds, for sensitizing a subject with cancer to a cancer therapy by inhibiting or down-regulating UROD.

Подробнее
Номер записи: 10
19-04-2012 дата публикации

Methods for detection, diagnosis and selective eradication of neoplasms in vivo using multidomain biotags

Номер: US20120095387A1
Автор: Marek Małecki, Raf Malecki
Принадлежит: Individual

A method for treating cancer in a subject is provided, the method comprising administering to the subject an effective dose of a multidomain biotag that targets one or more cancer cells; and exposing the subject to one or more rounds of radiation. The one or more rounds of radiation kills the one or more cancer cells targeted by the biotag, but, in general, do not kill healthy cells or kills a negligible number of healthy cells.

Подробнее
Номер записи: 11
19-04-2012 дата публикации

Ultrasound catheter for providing a therapeutic effect to a vessel of a body

Номер: US20120095389A1
Автор: Frederick J. Bennett, Gary Lichttenegger, James E. Rodriguey, John Zhang, Katsuro Tachibana
Принадлежит: Ekos LLC

The invention relates to a catheter system. The system comprises a catheter body having a chamber containing a low acoustic impedance medium. The catheter body includes an elongated body with an external surface and an ultrasound transducer having an external side between a first end and a second end. The ultrasound transducer is positioned over the external surface of the elongated body such that the first end is adjacent to the chamber.

Подробнее
Номер записи: 12
26-04-2012 дата публикации

Compositions and methods for biological remodeling with frozen particle compositions

Номер: US20120101738A1
Автор: Daniel B. Cook, Edward S. Boyden, Elizabeth A. Sweeney, Eric C. Leuthardt, Lowell L. Wood, JR., Nathan P. Myhrvold, Roderick A. Hyde
Принадлежит: SEARETE LLC

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Подробнее
Номер записи: 13
31-05-2012 дата публикации

Micro-Vesicles Providing Contrast To Target Tissue Electrical Property Gradients

Номер: US20120134924A1
Автор: David B. Chang, Jane F. Emerson, Martin Fessenmaier, Nicholas J. Witchey, Stephen Anthony Cerwin
Принадлежит: Magnetus LLC

Micro-vesicles that become acoustically sensitive in the presence of a Radio Frequency (RF) Electromagnetic (EM) field are presented. The micro-vesicles can comprise a main body having one or more affinity ligands configured to preferentially bind to a target tissue. Once bound, the micro-vesicles and the target tissue can be bathed in an RF EM field, which induces the target tissue or micro-vesicles to generate an acoustic signal. The micro-vesicles can also become receptive to acoustic energy. An acoustic therapeutic signal can be directed toward the target tissue and micro-vesicles, which causes therapeutic excitation of the micro-vesicles. The therapeutic excitation can include heating the target tissue, releasing a drug formulation, or other excitation. The disclosed techniques can be used with a high degree of precision to activate micro-vesicles local to the target tissue.

Подробнее
Номер записи: 14
31-05-2012 дата публикации

Methods to regulate polarization and enhance function of excitable cells

Номер: US20120136296A1
Автор: Gholam A. Peyman
Принадлежит: Individual

Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization and enhance function of such cells. The cells include retinal and other excitable cells.

Подробнее
Номер записи: 15
31-05-2012 дата публикации

Immunologic compounds for prevention, protection, prophylaxis or treatment of immunological disorders, infections and cancer

Номер: US20120136338A1
Автор: Denis Claude Roy, Luc Villeneuve, Marc Vaillancourt
Принадлежит: Individual

The present invention provides for methods of treating a cancer patient. In one methods, cancer cells are harvested from a patient. A therapeutic amount of a rhodamine derivative is then added to the harvested cancer cells. The harvested cells and the rhodamine derivative are then irradiated with a suitable wavelength and intensity for the selective killing of the cancer cells. The irradiated cancer cells are then mixed with antigen presenting cells to form a mixture. The mixture of cancer and antigen presenting cells are then injected into the patient. The present invention also provides for methods of inhibiting or treating an immunological disorder, infection, or a cancer in an individual.

Подробнее
Номер записи: 16
14-06-2012 дата публикации

Binary and tertiary galvanic particulates and methods of manufacturing and use thereof

Номер: US20120148633A1
Автор: Jue-Chen Liu, Leon B. Kriksunov, Luiz Arthur Bonaci Tessarotto, Michael Southall, Ying Sun
Принадлежит: Johnson and Johnson Consumer Companies LLC

The present invention relates to galvanic particulates, their methods of manufacture and uses in treatments are described. The galvanic particulates may be binary or tertiary galvanic particulates, for example, containing multiple layers or phases of conductive materials.

Подробнее
Номер записи: 17
14-06-2012 дата публикации

Process of constructing oxidation-reduction nanomedicine quantum dots room temperature quantum bit networks

Номер: US20120149581A1
Автор: Yan Fang
Принадлежит: Zhongshan Hospital Fudan University

Preparation of oxidation-reduction (redox) nano-medicine quantum dot room temperature superconductor quantum bit (qubit) networks includes processes of making unitary, binary, ternary, and/or quaternary liquid pharmaceutical ingredients of an antioxidase antioxidant, a β-adrenergic receptor agonist, a P 2 -purinergic receptor agonist, and/or a phenylalkylamine calcium channel blocker in combination with either 1:20 xanthine oxidase (XO):xanthine (X) or X alone in a liquid phase by using the L 16 (2) 15 and L 9 (3) 4 orthogonal optimization design protocols and modulating spatial distance constraint from about 0.1 Å to about 200 Å as well as a 10 class clean bottom-up self-assembly approach. Redox nano-drug quantum dot superconductor qubit network can be identified at room temperature by Planck constant ()-related qubit metrology of electron spins and polaritons (the quantum state of photon-exciton hybrid or photoelectron coupling/co-tunneling) through conducting atomic force microscopy (C-AFM) and/or laser micro- photoluminescence (PL) spectrum standard measurement method, wherein -related quantum continuous variables (QCVs) are derived from faster Fourier transformation (FFT) of average current-voltage (I-V) curves and PL spectra, their first derivatives of relative phases in frequency and time domains (dr/df=ΔE/ and dr/dt=ΔE/) and their FFTs to acquire Σ(2 n ), Σ(2 n ·2 n ), Σ(2 n+1 ), Σ(2 n ·2 n ), Σ(2 2n+1 ·2 2n+1 ) and/or Σ(2 2n+1 ) binary superconductor qubit matrix networks. Uses of this invention cover room temperature superconductor (resistance loss, insulator with conductor or ∞ conductance) quantum devices and quantum biology metrology, implanted nano-drug quantum dot diagnostic and therapeutic nanodevices and/or nano-bio-electrochemistry sensors with target-recognized functions.

Подробнее
Номер записи: 18
05-07-2012 дата публикации

Active ingredient comprising indocyanine green and/or infracyanine green

Номер: US20120172408A1
Автор: Reinhardt Thyzel
Принадлежит: A R C LASER GmbH

The present invention relates to an active ingredient including indocyanine green and/or infracyanine green for use in treating dental or periodontal infectious diseases under irradiation with light, more particularly laser light, from a wavelength range between 790 nm and 830 nm.

Подробнее
Номер записи: 19
05-07-2012 дата публикации

Chroman derivatives, medicaments and use in therapy

Номер: US20120172424A1
Автор: Alan Husband, Andrew Heaton
Принадлежит: Marshall Edwards Inc

Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Подробнее
Номер записи: 20
26-07-2012 дата публикации

System for defining energy field characteristics to illuminate nano-particles used to treat invasive agents

Номер: US20120190910A1
Автор: Andrew C. Updegrave, Daniel B. McKenna, Karl M. Frantz, Martin A. Huisjen
Принадлежит: Actium Biosystems LLC

The Invasive Agent Treatment System incorporates the pairing of energy fields with nano-particles to cause a thermal effect in the nano-particles, which thermal effect is transmitted into the biological cells of the invasive agent. The energy fields are derived from at least one or a combination of the following: an electric field, a magnetic field, an electromagnetic field (EM), an acoustic field, and an optical field. The Invasive Agent Treatment System provides the necessary coordination among the characteristics of the nano-particles, concentration of nano-particles, duration of treatment, and applied fields to enable the generation of precisely crafted fields and their application in a mode and manner to be effective with a high degree of accuracy.

Подробнее
Номер записи: 21
09-08-2012 дата публикации

Methods and Devices for Sustained In-Vivo Release Of an Active Agent

Номер: US20120201800A1
Автор: John W. Higuchi, Matthew S. Hastings, S. Kevin Li, William I. Higuchi
Принадлежит: Aciont Inc

The present invention includes methods and devices for providing sustained in-vivo release of an active agent to a subject. In some aspects, such release may be achieved by reacting an active agent in-vivo with a depot forming agent in order to form a sustained release active agent depot inside the subject. The depot can then release the active agent over a sustained period of time.

Подробнее
Номер записи: 22
30-08-2012 дата публикации

Immunologically modified carbon nanotubes for cancer treatment

Номер: US20120220921A1
Автор: Wei R. Chen
Принадлежит: University of Central Oklahoma

A method for constructing a compound of immunologically modified nanotubes and method for using the compound to deliver immunoadjuvants to tumor cells and to produce targeted, synergistic photophysical and immunological reactions for cancer treatment. To prepare the immunologically modified nanotubes, carbon nanotubes are dissolved in a solution of glycated chitosan, an immunostimulant, hence using glycated chitosan as a surfactant for rendering the aqueous solution of nanotubes stable. The compound can be used for treatment of cancer. The method includes steps of intratumorally administering immunologically modified nanotubes and administering laser irradiation of the target tumor. The nanotube serves as a carrier to deliver immunoadjuvants to the tumor cells and serves as a light-absorbing agent in a cell body of a tumor in a host. Upon laser irradiation of target tumor cells, immunologically modified nanotubes inside the tumor cells can produce spatially and temporally synchronized photothermal and immunological reactions for cancer treatment.

Подробнее
Номер записи: 23
04-10-2012 дата публикации

Method and Composition to Increase Radiation-Induced Tumor Therapeutic Effects

Номер: US20120252883A1
Автор: Branka Stancevic, Dror Harats, Michel Sadelain, Nira Varda-Bloom, Richard N. Kolesnick, Zvi Fuks
Принадлежит: Memorial Sloan Kettering Cancer Center, Vascular Biogenics Ltd

Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.

Подробнее
Номер записи: 24
11-10-2012 дата публикации

Oral care compositions for use with an oral light device

Номер: US20120258053A1
Автор: Madhusudan Patel, Mahmoud Hassan, Rosa Paredes, Thomas Boyd
Принадлежит: Colgate Palmolive Co

Generally regarded as safe (GRAS) dyes can be used as photosensitizing dyes in oral compositions to provide anti-bacterial and anti-inflammatory efficacy. Embodiments include oral care compositions including photosensitizing dyes, methods of making the compositions, methods of using the compositions, and kits containing the compositions and light emitting devices.

Подробнее
Номер записи: 25
18-10-2012 дата публикации

GLYCO-SUBSTITUTED DIHYDROXY-CHLORINS AND ß-FUNCTIONALIZED CHLORINS FOR ANTI-MICROBIAL PHOTODYNAMIC THERAPY

Номер: US20120263625A1
Автор: Arno Wiehe, Burkhard Gitter, Christian B. W. STARK, Daniel Aicher, Volker Albrecht
Принадлежит: Ceramoptec GmbH, Ceramoptec Industries Inc

Antimicrobial molecular conjugates for the treatment and prevention of infectious diseases caused by pathogenic microorganisms in human and animals are provided. The key to these conjugates is connecting dihydroxychlorins or β-functionalized chlorins to carbohydrate moieties. These conjugates are found to be very effective in combating bacterial infections caused by Gram-positive and Gram-negative bacteria, including their resistant strains. Significantly, they are also effective in complex environments, including blood, serum, and other body fluids which are present in patient's body. A method of use to control pathogenic microorganisms in human and animals is also provided.

Подробнее
Номер записи: 26
08-11-2012 дата публикации

Nanoparticle loaded stem cells and their use in mri guided hyperthermia

Номер: US20120283503A1
Автор: Lyubov Ostrovska
Принадлежит: JOHNS HOPKINS UNIVERSITY

The present invention provides stem cells loaded with bi-functional magnetic nanoparticles (nanoparticle-loaded stem cells (NLSC)) that both: a) heat in an alternating magnetic field (AMF); and b) provide MRI contrast enhancement for MR-guided hyperthermia. The nanoparticles in the NLSC are non-toxic, and do not alter stem cell proliferation and differentiation, the nanoparticles do however, become heated in an alternating magnetic field, enabling therapeutic applications for cancer treatment. NLSC can deliver hyperthermia to hypoxic areas in tumors for sensitization of those areas to subsequent treatment, thus delivering therapy to the most treatment-resistant tumor regions. The heating of diseased tissue either results in direct cell killing or makes the tumor more susceptible to radio- and/or chemotherapy. The NLSC of the present invention can be used for MR image-guided hyperthermia in oncology, in stem cell research for cell tracking and heating, and for elimination of mis-injected stem cells.

Подробнее
Номер записи: 27
15-11-2012 дата публикации

Fused Ring Diarylamino Photosensitizers for Phototherapy

Номер: US20120289884A1
Автор: Amruta R. Poreddy, Raghavan Rajagopalan
Принадлежит: Mallinckrodt LLC

The invention relates generally to optical agents and methods of using optical agents for biomedical applications, including phototherapy. Provided are methods of using diarylamino compounds having a fused ring backbone providing phototherapeutic agents, including Type 1 phototherapeutic agents. Optical agents of the invention enable a versatile phototherapy platform for treatment of a range of pathological conditions, including the treatment of cancers, stenosis and inflammation. The invention further provides preparations and formulations comprising the diarylamino optical agents and related methods of making and using diarylamino optical agents in an in vivo or ex vivo biomedical procedure.

Подробнее
Номер записи: 28
06-12-2012 дата публикации

Magnetic nanostructures as theranostic agents

Номер: US20120308657A1
Автор: Kirsten L. Viola, Saurabh Sharma, Tadanori Tomita, Vinayak P. Dravid, William L. Klein
Принадлежит: Northwestern University

The present invention relates to magnetic nanostructures as theranostic agents, which provide dual function as diagnostic and therapeutic agents. In particular, the present invention relates to compositions comprising magnetic nanostructures and their use as targeted therapeutic agents for cancers (e.g., medulloblastoma) and Alzheimer's disease and related diseases and conditions.

Подробнее
Номер записи: 29
20-12-2012 дата публикации

Crosslinked Hydrogels and Related Method of Preparation

Номер: US20120321585A1
Автор: Fengfu Li, Jae-Il Ahn, May Griffith
Принадлежит: OTTAWA HEALTH RESEARCH INSTITUTE, UNIVERSITY OF OTTAWA

The present invention provides a method of manufacturing a hydrogel comprising the step of crosslinking a biopolymer using a carbodiimide crosslinker of Formula I wherein at least one of R 1 and R 2 is a functional group that is a bulky organic functional group. R 1 and R 2 can each independently be an optionally substituted saturated or unsaturated functional group selected from the group consisting of an alkyl, a cycloalkyl, a heterocyclic, and an aryl. The bulky organic functional group will slow down the crosslinking reaction of carbodiimide due to the steric effects and/or electronic effects, in comparison to a crosslinking reaction using EDC. Also provided are the hydrogels and ophthalmic devices prepared using the method of the invention and uses thereof.

Подробнее
Номер записи: 30
21-02-2013 дата публикации

Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

Номер: US20130045237A1
Автор: Oleg Iliich Epshtein, Sergey Alexandrovish Tarasov
Принадлежит: Individual

The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis A, B, C and other types of hepatitis, the diseases and conditions caused by HIV or associated with HIV, including AIDS.

Подробнее
Номер записи: 31
21-02-2013 дата публикации

Method of controlled delivery using sub-micron-scale machines

Номер: US20130046274A1
Автор: Courtney R. Thomas, Daniel P. Ferris, Jae-Hyun Lee, Jeffrey I. Zink, Jinwoo Cheon, Monty Liong, Sarah Angelos Henscheid
Принадлежит: UNIVERSITY OF CALIFORNIA

A method for controlled delivery of a substance into a body includes administering a plurality of containment vessels into the body, in which each of the plurality of containment vessels includes a quantity of the substance loaded therein prior to the administering; and providing a time-varying magnetic field such that the plurality of containment vessels are exposed thereto to cause a release of at least a portion of the substance from the plurality of containment vessels. Each of the plurality of containment vessels has an average outer diameter less than about 1 μm.

Подробнее
Номер записи: 32
14-03-2013 дата публикации

Composite comprising at least one type of perfluoroalkyl-perfluoro-phthalocyanine

Номер: US20130064712A1
Автор: Beate Roder, Christian Litwinski, Robert Gerdes, Sergiu M. Gorun
Принадлежит: Individual

The present invention relates to a composite comprising at least one type of perfluoroalkyl-perfluoro-phthalocyanine, and to a method of producing such composite. The present invention also relates to a method of generating singlet oxygen, a method of killing eukaryotic or prokaryotic cells and a method of sterilization, cleaning and/or decontamination. Moreover, the present invention relates to a composite or a device for use in a method of sterilization, cleaning and/or decontamination.

Подробнее
Номер записи: 33
11-04-2013 дата публикации

USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF

Номер: US20130090592A1
Автор: Godal Aslak, Klaveness Jo, Wulf Hans Christian
Принадлежит: PHOTOCURE ASA

The invention provides the use of a photosensitiser which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm(e.g. 5 to 40 mW/cm), (iv) said photoactivation is carried out with sunlight. Preferably, side-effects of PDT are prevented or reduced by using (iii) or (iv) in combination with (i) and/or (ii). 144.-. (canceled)45. A method of reducing or preventing side-effects in the photodynamic treatment of acne comprising:(a) administering to an area characterized by acne on a patient in need of such treatment a composition comprising methyl ALA ester at a concentration of less than 10%, or the equivalent concentration of a pharmaceutically acceptable salt, for a period of less than 2 hours, and(b) administering photoactivating light to the affected area.46. The method of claim 45 , wherein the administered compound is methyl ALA ester hydrochloride salt.47. The method of claim 45 , wherein the concentration of methyl ALA ester is in the range from 0.5 to 8% claim 45 , or the equivalent concentration of a pharmaceutically acceptable salt.48. The method of claim 47 , wherein the concentration of methyl ALA ester is in the range from 2 to 8% claim 47 , or the equivalent concentration of a ...

Подробнее
Номер записи: 34
25-04-2013 дата публикации

Radiotherapy enhancer

Номер: US20130101680A1
Автор: Masakazu Fukushima
Принадлежит: Individual

The present invention relates to a method of treating pancreatic cancer in a subject in need thereof by administering an effective amount of a composition containing (A) tegafur and (B) gimeracil in conjunction with radiotherapy.

Подробнее
Номер записи: 35
25-04-2013 дата публикации

Nano Mixed Metal Oxide Thin Film Photocatalyst Consisting Of Titanium, Indium and Tin

Номер: US20130102953A1
Автор: Ramesh Paul J Tangaraj, Subrahmanyam Aryasomayajula
Принадлежит: HCL TECHNOLOGIES LTD.

The present invention relates to a novel photocatalyst comprising Nano mixed metal oxides of titanium, Indium and tin as a thin film with nano sized grains, method of its preparation and applications. The photocatalyst disclosed herein can be used in oxygenation of human/mammalian blood along with all other applications of photocatalysts. A photocatalytic oxygenator for the oxygenation derives oxygen from the water content of mammalian blood. The photocatalyst disclosed herein can also be used for effluent treatments along with all other applications associated with photocatalysts. 1. A photocatalyst comprising mixed metal oxides of titanium , Indium and tin as a thin film with nano sized grains.214-. (canceled)15. The photocatalyst as claimed in claim 1 , wherein the atomic percentage of constituents are about 3.58-4.80 Indium claim 1 , about 0.29-0.32 Tin claim 1 , and about 0.62-0.72 Titanium claim 1 , as measured by EDX measurements on the thin films claim 1 , along with oxygen.16. The photocatalyst as claimed in claim 1 , wherein the photocatalyst consists of tin doped indium oxide (ITO) and titanium dioxide (TiO)17. The photocatalyst as claimed in claim 1 , wherein the photo energy required is any single or a range of wavelengths in the spectrum of 255 nm-1100 nm.18. A method making a photocatalyst consisting of a Titanium claim 1 , Indium and Tin mixed metal oxide thin film with nano sized grains comprising depositing the metal oxides by DC magnetron sputtering on a substrate followed by annealing.19. The method as claimed in claim 18 , wherein the substrate is quartz claim 18 , synthetic silicon dioxide claim 18 , soda lime glass claim 18 , poly-carbonates claim 18 , poly imides or a polymer.20. The method as claimed in claim 19 , wherein the substrate is quartz or synthetic silicon dioxide.21. The method as claimed in claim 18 , wherein the depositing of the metal oxides is performed at a temperature in the range of 300K to 400 K.22. The method as claimed ...

Подробнее
Номер записи: 36
02-05-2013 дата публикации

Lipid bilayer carrier for drugs or imaging agents

Номер: US20130108551A1
Автор: Erica Maria Gerarda Aussems-Custers, Holger Gruell, Johan Lub, Mariska De Smet, Sander Langereis
Принадлежит: KONINKLIJKE PHILIPS ELECTRONICS NV

Disclosed are carriers for drugs and/or MR imaging agents having a lipid bilayer shell comprising a phospholipid having two terminal alkyl chains, one being a short chain having a chain length of at most seven carbon atoms, the other being a long chain having a chain length of at least fifteen carbon atoms. The mixed long/short chain phospholipids serve to tune the release properties of the carrier. Preferred phospholipids are phosphatidylcholines.

Подробнее
Номер записи: 37
02-05-2013 дата публикации

Antibacterial and antifungal peptides

Номер: US20130108575A1
Автор: Chris Kaplan, Daniel K. Yarbrough, Jee-Hyun Sim, Jian He, Maxwell Anderson, Randal H. Eckert
Принадлежит: C3 Jian Inc

This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.

Подробнее
Номер записи: 38
09-05-2013 дата публикации

INACTIVATION OF MICROORGANISMS WITH MULTIDRUG RESISTANCE INHIBITORS AND PHENOTHIAZINIUMS

Номер: US20130115133A1
Автор: Hamblin Michael R., Tegos George P.
Принадлежит: The General Hospital Corporation

The present invention relates the use of phenothiaziniums and microbial MDR inhibitors to inactivate microorganisms. Methods of the present invention are useful in the treatment of living subjects and in the decontamination of inanimate objects and substances. 1. A method of inactivating microorganisms comprising contacting the microorganism with a phenothiazinium and a microbial MDR inhibitor and irradiating the phenothiazinium such that a phototoxic species is produced that inactivates the microorganism.2. The method of claim 1 , wherein the microorganism is selected from the group consisting of bacteria claim 1 , fungus claim 1 , protozoa claim 1 , virus claim 1 , parasite and yeast.3Staphylococcus, Streptococcus, Enterococcus, Mycobacterium, Pseudomonas, Salmonella, Shigella, Escherichia, Erwinia, Klebsiella, Borrelia, Treponema, Campylobacter, Helicobacter, Bordetella, Neisseria, Legionella, Leptospira, Serpulina, Mycoplasma, Bacteroides, Klebsiella, Yersinia, Chlamydia, Vibrio, Actinobacillus, Porphyria, Hemophilus, Helicobacter, Pasteurella, Pseudomonas, Peptostreptococcus, Listeria, Propionibacterium, Mycobacterium, CorynebacteriumDermatophilus.. The method of claim 2 , wherein the bacteria is of a genus selected from the group consisting of and4. The method of claim 1 , wherein the microorganism is a virus selected from the group consisting of HIV claim 1 , Hepatitis virus claim 1 , Influenza virus claim 1 , Rhinovirus claim 1 , Papilloma virus claim 1 , Measles virus claim 1 , Herpes virus claim 1 , Rotavirus claim 1 , Parvovirus claim 1 , Psittacosis virus claim 1 , and Ebola virus.5. The method of claim 1 , wherein the microorganism to be inactivated is in or on a living animal.6. The method of wherein the microorganism to be inactivated is located on the skin or mucous membranes of the living animal claim 5 , or within wounds claim 5 , cuts or abrasions of the living animal.7. The method of claim 5 , wherein the living animal is a human.8. The method of ...

Подробнее
Номер записи: 39
09-05-2013 дата публикации

Rare Earth-Doped Up-Conversion Nanoparticles for Therapeutic and Diagnostic Applications

Номер: US20130115295A1
Автор: Lu Patrick Y., Wang Qiang, Yang Harry Hongjun
Принадлежит:

This invention provides a composition matter comprising rare earth-doped up-conversion nanoparticles (UCNPs) encapsulated with a silica shell. In one embodiment, a photosensitizer is incorporated into the silica shell. In another embodiment, the composition further comprises a targeting molecule. In still another embodiment, a small interfering RNA (siRNA) molecule is also attached to the silica shell with the targeting molecule. The invention further provides methods for synthesizing such compositions and for using them in therapeutic and diagnostic applications. These applications use infrared or near infrared activation to excite the UCNPs. 1. A composition comprising rare earth-doped up-conversion nanoparticles (UCNPs) encapsulated with a silica shell wherein a photosensitizer is incorporated into the silica shell.2. The composition of further comprising a targeting molecule attached to the silica shell.3. The composition of wherein the rare earth element is selected from the group consisting of Yttrium (Y) claim 2 , Holmium (Ho) claim 2 , Erbium (Er) claim 2 , Thulium (Tm) claim 2 , and Ytterbium (Yb).4. The composition of wherein the UCNPs have the formula NaYF4: Yb-Ln claim 3 , wherein Ln is Er claim 3 , Tm claim 3 , or Ho.5. (canceled)6. The composition of wherein the UCNPs produce fluorescent emission in the visible light region upon excitation with an infrared (IR) or a near infrared (NIR) light irradiation source.7. The composition of wherein the photosensitizer comprises a light-sensitive chemical that produces singlet oxygen when excited with light of a specific wavelength.810.-. (canceled)11. The composition of wherein the silica shell comprises functional groups with —O—Si—O bonds.12. The composition of wherein the silica shell is functionalized with a chemical with one functional group.13. The composition of wherein the silica shell is functionalized with a chemical with two or more functional groups.1417.-. (canceled)18. The composition of wherein ...

Подробнее
Номер записи: 40
16-05-2013 дата публикации

Prodrug compositions, prodrug nanoparticles, and methods of use thereof

Номер: US20130122100A1
Автор: Dipanjan Pan, Gregory M. Lanza
Принадлежит: Washington University in St Louis WUSTL

Nanoparticles comprising a prodrug and prodrugs linked to phospholipids, wherein the linkages facilitate release of the prodrugs from the nanoparticles to sites within a target cell or cell membrane by fusion of the particle and the cell membrane are disclosed. Also disclosed are methods for producing and using the nanoparticles and their constituents.

Подробнее
Номер записи: 41
16-05-2013 дата публикации

TARGETING MICROBUBBLES

Номер: US20130123781A1
Автор: Chung Hoyong, Fitzgerald Alissa M., GRUBBS Robert H., Kenny Thomas W., Stoller Marshall L., Thomas Renee M.
Принадлежит: California Institute of Technology

This invention related to manufactured microbubbles, as well as methods of using manufactured microbubbles, for example, in medicinal applications. The invention pertains to the physical structure and materials of the microbubbles, as well as to methods for manufacturing microbubbles, methods for targeting microbubbles for specific medicinal applications, and methods for delivering microbubbles in medical treatment. 1. A targeting microbubble comprising:(a) a core containing a fluid having a normal boiling point less than about 30° C.;(b) an anchoring moiety comprising a bio-lipid, protein, surfactant, or synthetic polymer; and (i) a chemical group having an affinity for a metal-containing material; or', '(ii) a cell specific ligand., '(c) a targeting moiety comprising2. The targeting microbubble of claim 1 , wherein the anchoring moiety and the targeting moiety are linked via a covalent claim 1 , ionic claim 1 , or hydrogen-bonding linkage.3. The targeting microbubbles of claim 2 , wherein the anchoring moiety covalently attached to the targeting moiety.4. The targeting microbubble of claim 1 , further comprising a polymeric linker that covalently attaches the anchoring moiety to the targeting moiety.5. The targeting microbubble of claim 1 , wherein the fluid is air claim 1 , CO claim 1 , a fluorinated or perfluorinated Chydrocarbon claim 1 , or a combination thereof.6. The targeting microbubble of claim 5 , wherein the fluorinated hydrocarbon is perfluoropropane or perfluoropentane.7. The targeting microbubble of claim 5 , wherein the targeting moiety comprises a chemical group having an affinity for a metal-containing material.8. The targeting microbubble of claim 1 , wherein the chemical group comprises a chelant having at least two amino claim 1 , carboxy claim 1 , hydroxyl claim 1 , phosphoryl claim 1 , or thiol groups claim 1 , or a combination thereof claim 1 , said chelant having an affinity for the metal-containing material.9. The targeting microbubble of ...

Подробнее
Номер записи: 42
23-05-2013 дата публикации

Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue

Номер: US20130129616A1
Автор: Annette Bianchi, David Hung, Eyal Ron, Julian Nikolchev, Linda K. Gont, Susan Love, Tina Patel
Принадлежит: Atossa Genetics Inc

The invention is a gel composition for delivery to a breast milk duct prior to surgical excision of breast tissue including cancerous lesions. The invention also provides methods of mapping all or nearly all of a breast milk duct prior to surgical excision of breast tissue, and method of identifying part or all of a breast duct or ducts as a surgical aide to a breast surgeon. Kits to support these methods and including these compositions are also provided.

Подробнее
Номер записи: 43
23-05-2013 дата публикации

MULTIMODAL NANOPARTICLES FOR NON-INVASIVE BIO-IMAGING

Номер: US20130129633A1
Автор: BENGTSSON NICLAS, BROWN SCOTT CHANG, GROBMYER STEPHEN R., JIANG HUABEI, MOUDGIL BRIJ M., SANTRA SWADESHMUKUL, SCOTT EDWARD W., SHARMA PARVESH, WALTER GLENN A., ZHANG QIZHI
Принадлежит: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

Multimodal nanoparticles are nanoparticles containing contrast agents for PAT and one or more of luminescence imaging, x-ray imaging, and/or MRI. The multimodal nanoparticles can have a dielectric core comprising an oxide with a metal coating on the core. The particles can be metal speckled. The multimodal nanoparticles can be used for therapeutic purposes such as ablation of tumors or by neutron capture in addition to use as contrast agents for imaging. 1. A method for multimodal bio-imaging comprising:providing a multimodal nanoparticle comprising a dielectric core comprising at least one oxide, a speckled metal deposition on said core where said metal deposition and said dielectric core have an interface with interpenetrated gradient, and a plurality of at least one moiety that exhibits luminescence, magnetic or paramagnetic properties, x-ray opacity, or any combination thereof, wherein said multimodal nanoparticle is a contrast agent for photo acoustic tomography (PAT) imaging and at least one of luminescence imaging, magnetic resonance (MR) imaging and x-ray imaging;introducing said multimodal nanoparticle to a desired location; andimaging the desired location by photo acoustic tomography (PAT) and at least one of magnetic resonance, luminescence, and x-rays, wherein said multimodal nanoparticle enhances the contrast observed in said imaging wherein said imagings are performed simultaneously or sequentially.2. A method of therapy comprising:providing a multimodal nanoparticle comprising a dielectric core comprising at least one oxide, a speckled metal deposition on said core where said metal deposition and said dielectric core have an interface with interpenetrated gradient, and a plurality of at least one moiety that exhibits luminescence, magnetic or paramagnetic properties, x-ray opacity, or any combination thereof, wherein said multimodal nanoparticle is a contrast agent for photo acoustic tomography (PAT) imaging and at least one of luminescence imaging, ...

Подробнее
Номер записи: 44
23-05-2013 дата публикации

Cancer Therapy Via Selective Uptake of Specialized Nanoparticles in Cancer Cells

Номер: US20130129664A1
Автор: Gesguiere Andre, Hu Zhongjian, Mathew Mona
Принадлежит: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.

Disclosed herein are polymer/fullerene nanoparticles that have selective uptake into cancer cells, and which, upon being taken into the cancer cells induce apoptosis. Induction of apoptosis can be controlled by activation of the nanoparticles. Activation can occur such as by photoactivation, or other means. 1. A method for treating , or preventing the reoccurrence , of cancer in a subject , said method comprising administering a therapeutically effective amount of conjugated polymer nanoparticles or composite conjugated polymer nanoparticles to said subject.2. The method of claim 1 , wherein said nanoparticles are produced via an emulsion process.3. The method of claim 1 , wherein the conjugated polymer nanoparticles or composite conjugated polymer nanoparticles are light absorbing.4. The method of claim 1 , wherein said conjugated polymer nanoparticles or composite conjugated polymer nanoparticles create ROS upon photoactivation.5. The method of claim 1 , wherein the nanoparticles are polymer/fullerene nanoparticles.6. The method of claim 1 , wherein the cancer is breast cancer claim 1 , testicular cancer claim 1 , lung cancer claim 1 , melanoma claim 1 , brain cancer claim 1 , myeloma claim 1 , Hodgkin's disease claim 1 , hepatoma claim 1 , stomach cancer claim 1 , bladder cancer claim 1 , uterine cancer claim 1 , neuroblastoma claim 1 , thyroid cancer claim 1 , sarcoma claim 1 , cervical cancer claim 1 , Wilm's tumor claim 1 , colorectal cancer claim 1 , pancreatic cancer claim 1 , skin cancer claim 1 , prostate cancer claim 1 , ovarian cancer claim 1 , kidney cancer claim 1 , lymphoma claim 1 , acute myelogenous leukemia claim 1 , acute lymphocytic leukemia claim 1 , multiple myeloma claim 1 , ependymoma claim 1 , chronic lymphocytic leukemia claim 1 , myelodysplastic syndrome claim 1 , or chronic myelogenous leukemia.7. A method for preventing claim 1 , treating claim 1 , or managing cancer resulting in a reduction in bulk tumor size and/or a reduction in ...

Подробнее
Номер записи: 45
23-05-2013 дата публикации

TUMOR PROLIFERATION INHIBITOR CONTAINING ULTRASOUND-SENSITIVE SUBSTANCE AND METHOD FOR INHIBITING TUMOR PROLIFERATION BY USING TUMOR PROLIFERATION INHIBITOR AND LOW-INTENSITY PULSED ULTRASOUND WAVES

Номер: US20130129799A1
Автор: SHIBAGUCHI Hirotomo, Tsuru Hirofumi
Принадлежит: Fukuoka University

Provided are a tumor proliferation inhibitor and a method for inhibiting tumor proliferation both of which can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. The present invention provides a tumor proliferation inhibitor containing an ultrasound-sensitive substance and an acoustic cavitation phenomenon-enhancing substance, and provides a method for inhibiting tumor proliferation that can exhibit a tumor proliferation-inhibitory effect using the tumor proliferation inhibitor in combination with low-intensity pulsed ultrasound of a degree that is used in ultrasound diagnosis, and that can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. 16-. (canceled)7. A tumor proliferation inhibitor containing an ultrasound-sensitive substance substantially unreactive with a light and an acoustic cavitation phenomenon-enhancing substance.8. The tumor proliferation inhibitor as claimed in claim 7 , wherein said ultrasound-sensitive substance is a porphyrin derivative or a xanthene derivative.10. The tumor proliferation inhibitor as claimed in claim 7 , wherein said acoustic cavitation phenomenon-enhancing substance is gas-filled bubbles.11. The tumor proliferation inhibitor as claimed in claim 10 , wherein said gas-filled bubbles are microbubbles or nanobubbles.12. The tumor proliferation inhibitor as claimed in claim 10 , wherein said gas-filled bubbles are sonazoid or levovist.13. A method for the treatment of cancers using a tumor proliferation inhibitor containing an ultrasound-sensitive substance substantially unreactive with a light and an acoustic cavitation phenomenon-enhancing substance.14. The method as claimed in claim 13 , wherein said ultrasound-sensitive substance is a porphyrin derivative or a xanthene derivative.16. The method as claimed in claim 13 , wherein said acoustic cavitation phenomenon-enhancing substance is gas-filled bubbles.17. The method as claimed in claim 16 , wherein ...

Подробнее
Номер записи: 46
23-05-2013 дата публикации

Use of a peptide enhancing the ability of radiation therapy to kill cancer cells

Номер: US20130130991A1
Автор: Christian Widmann, Oscar Matzinger
Принадлежит: UNIVERSITÉ DE LAUSANNE

The present invention relates to a peptide consisting essentially of the N2 sequence of the RasGAP protein, a bio logically active fragment thereof, or a variant thereof, which is useful for the preparation of a medicament for the treatment of cancer. Furthermore, it relates to a method of treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of the peptide of the invention.

Подробнее
Номер записи: 47
23-05-2013 дата публикации

Methods of Preventing Platelet Alloimmunization and Alloimmune Platelet Refractoriness and Induction of Tolerance in Transfused Recipients

Номер: US20130131639A1
Автор: Sherrill J. Slichter
Принадлежит: Puget Sound Blood Center

Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. Methods are provided to modify donor whole blood or platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness.

Подробнее
Номер записи: 48
30-05-2013 дата публикации

ANTICANCER AGENT DELIVERY SYSTEM USING pH-SENSITIVE METAL NANOPARTICLES

Номер: US20130138032A1
Автор: Kim Sungjee, Nam Jutaek
Принадлежит:

The present invention relates to a method for effectively delivering an anticancer drug into cancer cells by binding the anticancer drug to pH-sensitive metal nanoparticles so as to be separated from cancer cells. The pH-sensitive metal nanoparticles according to the present invention may be heated by photothermal therapy, thereby effectively killing cancer cells in conjunction with the isolated anticancer drug. 1. A method for delivering an anticancer drug to cells , comprising:conjugating the anticancer drug to a pH-sensitive metal nanoparticle; andreleasing the anticancer agent in an acidic pH condition.3. The method of claim 1 , wherein the anticancer agent has a primary amine group or OH group.4. The method of claim 3 , wherein the anticancer agent is selected from the group consisting of doxorubicin claim 3 , Methotrexate claim 3 , Paclitaxel claim 3 , Cisplatin claim 3 , Bleomycin and a combination thereof.5. The method of claim 2 , wherein the anticancer drug is conjugated to the compound of Chemical Formula 1 by means of EDC and sulfo-NHS.6. The method of claim 1 , wherein the anticancer drug is released from the metal nanoparticle by hydrolysis.8. The method of claim 1 , wherein the anticancer drug is released in a sustained manner.9. A pH-sensitive metal nanoparticle for therapy of cancer claim 1 , being loaded with an anticancer drug claim 1 , wherein the anticancer drug is released from the metal nanoparticle in an acidic pH condition.11. The pH-sensitive metal nanoparticle of claim 9 , ranging in size from about 5 to 15 nm.12. The pH-sensitive metal nanoparticle of claim 9 , wherein the anticancer drug is released by hydrolysis.13. The pH-sensitive metal nanoparticle of claim 9 , wherein the anticancer drug is selected from the group consisting of doxorubicin claim 9 , Methotrexate claim 9 , Paclitaxel claim 9 , Cisplatin claim 9 , Bleomycin and a combination thereof.18. The pH-sensitive metal nanoparticle of claim 17 , wherein the dye is Alexa Fluor ...

Подробнее
Номер записи: 49
06-06-2013 дата публикации

Novel hydroxamates as therapeutic agents

Номер: US20130142758A1
Автор: Chitra Baskaran, Erik J. Verner, James Robinson, Joseph J. Buggy, Martin Sendzik
Принадлежит: Pharmacyclics LLC

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

Подробнее
Номер записи: 50
13-06-2013 дата публикации

SENSITIZATION OF TUMOR CELLS TO RADIATION THERAPY THROUGH ADMINISTRATION OF ENDOTHELIN AGONISTS

Номер: US20130150649A1
Автор: Gulati Anil, Lenaz Luigi, Reddy Guru
Принадлежит:

Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETagonist IRL1620. 1. A radiation combination therapy contributing to the treatment of a lymphoma in a patient in need thereof , the therapy comprising{'sub': 'B', 'administering a first radiation sensitizing compound and a second radiation sensitizing compound to the patient, wherein administration of the first radiation sensitizing compound increases oxygenation of the lymphoma, thereby sensitizing the lymphoma to radiation-induced cellular damage, and wherein the first radiation sensitizing compound is an endothelin B (ET) receptor agonist; and'}administering a radiation to the patient, wherein administration of the radiation induces cellular damage to the lymphoma, thereby treating the lymphoma in the patient;wherein administration of the first and the second radiation sensitizing compounds occurs before administration of the radiation to the patient.2. The radiation combination therapy according to claim 1 , wherein the ETreceptor agonist includes ET-1 claim 1 , ET-2 claim 1 , ET-3 claim 1 , BQ3020 claim 1 , IRL1620 claim 1 , sarafotoxin S6c claim 1 , or [Ala]ET-1 claim 1 , or combinations thereof.3. The radiation combination therapy according to claim 2 , wherein the ETreceptor agonist is an IRL1620.4. The radiation combination therapy according to claim 1 , wherein the second radiation sensitizing compound includes metronidazole claim 1 , misonidazole claim 1 , desmethylmisonidazole claim 1 , pimonidazole claim 1 , etanidazole claim 1 , nimorazole claim 1 , mitomycin C claim 1 , RSU 1069 claim 1 , SR 4233 claim 1 , E09 claim 1 , RB 6145 claim 1 , nicotinamide claim 1 , 5-bromodeoxyuridine claim 1 , 5-iododeoxyuridine claim 1 , bromodeoxycytidine claim 1 , fluorodeoxyuridine claim 1 , hydroxyurea claim 1 , or cisplatin claim 1 , or mixtures thereof.5. The radiation combination therapy according to claim 1 , wherein administration of the first ...

Подробнее
Номер записи: 51
20-06-2013 дата публикации

MANUFACTURE, COMPOSITIONS AND USES OF COAGULATION FACTOR VIIa MODULATOR

Номер: US20130158089A1
Автор: David Loury, Tarak Mody
Принадлежит: Pharmacyclics LLC

Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I:

Подробнее
Номер записи: 52
04-07-2013 дата публикации

IMMUNOLOGICALLY MODIFIED CARBON NANOTUBES FOR CANCER TREATMENT

Номер: US20130172848A1
Автор: CHEN WEI R.
Принадлежит: THE UNIVERSITY OF CENTRAL OKLAHOMA

A method for constructing a compound of immunologically modified nanotubes and method for using the compound to deliver immunoadjuvants to tumor cells and to produce targeted, synergistic photophysical and immunological reactions for cancer treatment. To prepare the immunologically modified nanotubes, carbon nanotubes are dissolved in a solution of glycated chitosan, an immunostimulant, hence using glycated chitosan as a surfactant for rendering the aqueous solution of nanotubes stable. The compound can be used for treatment of cancer. The method includes steps of intratumorally administering immunologically modified nanotubes and administering laser irradiation of the target tumor. The nanotube serves as a carrier to deliver immunoadjuvants to the tumor cells and serves as a light-absorbing agent in a cell body of a tumor in a host. Upon laser irradiation of target tumor cells, immunologically modified nanotubes inside the tumor cells can produce spatially and temporally synchronized photothermal and immunological reactions for cancer treatment. 120-. (canceled)21. A method of delivering an immunostimulant to a cell body and of producing targeted , synergistic photophysical and immunological reactions comprising:coating a nanostructure with glycated chitosan;penetrating a cell membrane of a cell body with said nanostructure.22. The method according to wherein:said nanostructure is a singled-walled carbon nanotube.23. The method according to further comprising the step of:irradiating said nanostructure after said step of penetrating.24. The method according to wherein:said step of irradiating includes exposing said cell body with near-infrared light for facilitating synergistic, simultaneous photothermal and immunological reactions.25. The method according to wherein:said near-infrared light is produced by a 980-nm laser.26. The method according to wherein:said laser has a laser power density of 0.75 to 2 W/cm; andsaid step of irradiating comprises administering ...

Подробнее
Номер записи: 53
11-07-2013 дата публикации

GOLD PARTICLES AND METHODS OF MAKING AND USING THE SAME IN CANCER TREATMENT

Номер: US20130177523A1
Автор: GHANDEHARI Hamid, GORMLEY Adam, Larson Nate, Ray Abhijit
Принадлежит: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Described herein are gold particles that can be used to reduce tumor proliferation and treat cancer. In certain aspects, the gold particles can be modified in order to enhance selectivity and uptake of the particles by cancer cells. In certain aspects, the modified gold particles have a targeting group attached to the particle via a linker. The gold particles described herein can be used in combination with other anti-cancer agents in order to enhance overall cancer treatment. Methods for making and using the gold particles are also described herein. 2. The composition of claim 1 , wherein the gold particle is a spherical particle claim 1 , a cage claim 1 , a disc or a rod.3. The composition of claim 1 , wherein the gold particle is a rod having a diameter from 5 nm to 100 nm and length from 10 nm to 800 nm.4. The composition of claim 1 , wherein the linker comprises a hydrophobic linker.5. The composition of claim 1 , wherein the linker comprises a hydrophilic linker.6. The composition of claim 5 , wherein the hydrophilic linker comprises the polymerization product of hydroxyalkyl methacrylate (HEMA) claim 5 , hydroxyalkyl acrylate claim 5 , N-vinyl pyrrolidone claim 5 , N-methyl-3-methylidene-pyrrolidone claim 5 , allyl alcohol claim 5 , N-vinyl alkylamide claim 5 , N-vinyl-N-alkylamide claim 5 , acrylamides claim 5 , methacrylamide claim 5 , (lower alkyl)acrylamides and methacrylamides claim 5 , hydroxyl-substituted (lower alkyl)acrylamides and methacrylamides claim 5 , and any combination thereof.7. The composition of claim 5 , wherein the hydrophilic linker comprises a polymer of ethylene glycol claim 5 , propylene glycol claim 5 , or block co-polymers thereof.8. The composition of claim 5 , wherein the hydrophilic linker comprises poly(ethylene glycol) having a molecular weight from 100 to 30 claim 5 ,000.9. The composition of claim 1 , wherein the functional group is a hydroxyl group claim 1 , an alkoxy group claim 1 , a carboxy group claim 1 , a carbonyl ...

Подробнее
Номер записи: 54
18-07-2013 дата публикации

COMPOSITIONS AND METHODS FOR CANCER TREATMENT USING TARGETED CARBON NANOTUBES

Номер: US20130183354A1
Автор: Harrison, JR. Roger G., Neves Luis Filipe Ferreira, Resasco Daniel E.
Принадлежит:

A method for detecting and/or destroying cancer tumors is based on the concept of associating a linking protein or linking peptide to carbon nanotubes to form a protein-carbon nanotube complex. 1. A method of treating a cancer tumor or cancer cells in a patient , the method comprising the steps of:administering a composition comprising a protein-carbon nanotube complex to the patient, the protein-carbon nanotube complex comprising a protein or peptide operatively attached to a single-walled carbon nanotube (SWNT) wherein the SWNT is semiconducting and nonmetallic and wherein the protein or peptide of the protein-carbon nanotube complex comprises a binding protein or peptide that specifically binds to an external receptor or binding site on a tumor vasculature endothelial cell or on a cancer cell whereby the protein-carbon nanotube complex preferentially binds to the external receptor or binding site on an outer surface of the tumor vasculature endothelial cell or on an outer surface of the cancer cell in the patient; andexposing the patient to electromagnetic radiation comprising a wavelength absorbable by the SWNT, thereby causing elevation of the temperature of the SWNT of the protein-carbon nanotube complex to a temperature which induces damage and/or death of the tumor vasculature endothelial cell or cancer cell to which the protein-carbon nanotube complex is bound.2. The method of claim 1 , wherein the external receptor or binding site is specific for the tumor vasculature endothelial cells or cancer cells.3. The method of claim 1 , wherein the protein-carbon nanotube complex comprises at least one SWNT having a (n claim 1 ,m) structure selected from the group consisting of (6 claim 1 ,5) claim 1 , (7 claim 1 ,6) claim 1 , (8 claim 1 ,7) claim 1 , (7 claim 1 ,5) claim 1 , (8 claim 1 ,6) claim 1 , (9 claim 1 ,7) claim 1 , and (9 claim 1 ,8).4. The method of claim 1 , wherein the composition comprises a plurality of protein-carbon nanotube complexes having a ...

Подробнее
Номер записи: 55
25-07-2013 дата публикации

Ablative immunotherapy

Номер: US20130189301A1
Автор: Har-Noy Michael
Принадлежит:

The disclosure herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues. The immunotherapy relates to first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing in situ necrosis or apoptosis in a tumor or pathogen infected lesion. Necrosis or apoptosis can be induced by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue. One or more doses of allogeneic cells (e.g., Th1 cells) are then delivered within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen. 1. A therapeutic composition for treating a tumor or pathogen in a patient comprising:allogeneic cells; andantigens comprising the product of tumor necrosis or pathogen infected tissue necrosis, wherein the antigens are generated in situ, whereby the allogeneic cells and the in situ generated antigens elicit an immune response by the patient to create an anti-tumor or anti-pathogen immunity.2. The composition of further comprising a priming composition wherein the priming composition comprises allogeneic cells.3. The composition of wherein the antigens are generated in situ by ablation of the tumor or pathogen infected tissue.4. The composition of wherein the ablation is by cryoablation.5. The composition of wherein the ablation is by electroporation.6. The composition of wherein the antigens comprise tumor or pathogen antigens claim 1 , heat shock proteins and combinations thereof7. The composition of wherein the allogeneic cells are activated T-cells.8. The composition of wherein the ...

Подробнее
Номер записи: 56
25-07-2013 дата публикации

Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections

Номер: US20130189364A1
Автор: Robert Sabin
Принадлежит: Individual

A composition and method for potentiating, sensitizing, and/or amplifying at least one adjuvant pharmaceutical targeting at least one latent viral infection in a patient is provided. In one embodiment, the composition is administered to potentiate, sensitize and/or amplify an adjuvant pharmaceutical targeting at least one latent viral infection such as those which are currently being investigated for use with anti-HIV drugs/antiretrovirals HAART.

Подробнее
Номер записи: 57
01-08-2013 дата публикации

Magnetic Nanoparticles

Номер: US20130195767A1
Автор: Lee Hakho, Weissleder Ralph, Yoon Tae-Jong
Принадлежит:

A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles. 1. A nanoparticle comprising:a ferromagnetic core;a superparamagnetic shell surrounding the magnetic core.2. The nanoparticle of claim 1 , wherein the nanoparticle has a diameter greater than or equal to about 2 nm.3. The nanoparticle of claim 1 , wherein the ferromagnetic inner core has a core diameter in the range of about 1 nm to about 15 nm4. The nanoparticle of claim 1 , wherein the super-paramagnetic shell has a thickness greater than or equal to about 0.1 nm.5. The nanoparticle of claim 1 , wherein the ferromagnetic core comprises Fe claim 1 , Co claim 1 , Ni claim 1 , FePt or SmCo.6. The nanoparticle of claim 1 , wherein the superparamagnetic shell comprises an oxide of a magnetic material.7. The nanoparticle of claim 1 , wherein the super-paramagnetic shell comprises a dopant material.8. The nanoparticle of claim 7 , wherein the dopant comprises a metal selected from the group consisting of Mn claim 7 , Co claim 7 , Ni claim 7 , Zn claim 7 , and ZnMn.9. The nanoparticle of claim 1 , further comprising a coating on the super-paramagnetic shell claim 1 , wherein the coating is configured to increase the aqueous solubility of the nanoparticle.10. The nanoparticle of claim 9 , wherein the coating comprises 2 claim 9 , 3-dimercaptosuccinic acid (DMSA).11. The nanoparticle of claim 1 , further comprising a coating on the super-paramagnetic shell claim 1 , wherein the coating is configured to bind the nanoparticle to a target molecule.12. The nanoparticle of claim 1 , further comprising a dextran polymer coating on the superparamagnetic shell.13. A method of forming a nanoparticle claim 1 , the method comprising:forming one or more ferromagnetic ...

Подробнее
Номер записи: 58
01-08-2013 дата публикации

Core-Excited Nanoparticles and Methods of Their Use in the Diagnosis and Treatment of Disease

Номер: US20130195979A1
Автор: Tersigni Samuel Harry
Принадлежит:

Core-excited nanoparticle thermotherapy (CENT) represents a new paradigm in thermotherapy. The CENT method employs core-shell nanoparticles. The core of the nanoparticles is formed from one or more core-exciting, energy absorbing materials which absorbs core-exciting energy, either from an external energy source or from an energy source within the nanoparticle core (e.g., one or more radionuclides which undergo decay). Upon excitation by the core-exciting energy, the one or more core-exciting, energy absorbing materials reemit energy. A shell surrounds the particle nanoparticle core. The energy reemitted by the one or more core-exciting, energy absorbing materials is absorbed by the nanoparticle shell, so as to heat the shell of the nanoparticle. The heated nanoparticle then heats the surrounding region, to a temperature sufficient to detect, affect, damage or destroy the targeted cell or material. These core-shell nanoparticles can be administered to a patient in need thereof to treat diseases or disorders, including cancer. CENT nanoparticles can be optionally be bound to targeting agents that deliver them to the region of the diseased cell. 1. Nanoparticles comprising:a) a core comprising one or more core-exciting energy absorbing materials which i) absorbs core-exciting energy, and ii) subsequently reemits energy, andb) a shell surrounding the core, which comprises one or more materials which absorbs the energy reemitted from the one or more core-exciting energy absorbing materials, and then emits heat in sufficient quantity to kill or damage cells or tissue.2. The nanoparticles of claim 1 , wherein the nanoparticles are nanospheres or nanorods with an average length or average diameter less than 1000 nm claim 1 , preferably less than 500 nm claim 1 , and most preferably less than 300 nm.3. The nanoparticles of claim 1 , wherein the one or more core-exciting energy absorbing materials are scintillators claim 1 , long-lived phosphors claim 1 , persistent ...

Подробнее
Номер записи: 59
08-08-2013 дата публикации

Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed by post-loading photosensitizer and fluorophore to polyacrylamide nanoparticles

Номер: US20130202525A1
Автор: Anurag Gupta, Munawwar Sajjad, Raoul Kopelman, Ravindra K. Pandey
Принадлежит: Health Research Inc, Research Foundation of State University of New York, University of Michigan

A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and a postloaded imaging agent and methods for making and using same.

Подробнее
Номер записи: 60
08-08-2013 дата публикации

PAA NANOPARTICLES FOR PET IMAGING AND PDT TREATMENT

Номер: US20130202526A1
Автор: Gupta Anurag, Kopelman Raoul, Pandey Ravindra K., Sajjad Munawwar
Принадлежит:

PAA nanoparticles containing at least one tetrapyrrolic photosensitizer and at least one PET imaging agent. 1. A composition comprising PAA nanoparticles containing at least one tetrapyrollic photosensitizer and a PET imaging agent.2. The composition of wherein at least one photosensitizer comprises a moiety containing I and also acts as an imaging agent.4. The composition of wherein the photosensitizer is post loaded onto the nanoparticle after nanoparticle formation.5. The composition of where the photosensitizer is selected from the group consisting of a chlorins claim 1 , bacteriochlorins claim 1 , pyropheophorbides claim 1 , or mixtures thereof.6. The composition of wherein the imaging agent is a I labeled compound.7. The composition of where the photosensitizer and imaging agent are the same compound.9. The composition of wherein the imaging agent is a PET imaging agent.10. The composition of wherein the nanoparticle contains a targeting moiety.11. The composition of wherein the targeting moiety is a peptide claim 10 , folic acid or a carbohydrate.12. A method for making PAA nanoparticle's containing a photosensitizer and an imaging agent by post loading a photosensitizer and a PET imaging agent onto a pre-prepared PAA nanoparticle.14. The method of where the photosensitizer is HPPH.15. The composition of where the photosensitizer is HPPH.16. The composition of where the imaging agent is HPPH substituted with a moiety containing I.17. The method of where the imaging agent is HPPH substituted with a moiety containing I.18. The composition of wherein the photosensitizer and imaging agent are postloaded onto pre-prepared PAA nanoparticles.19. The composition of where the numerical ratio of postloaded photosensitizer to imaging agent is from 1 to 1 to 10 to 1.20. The composition of where the numerical ratio of postloaded photosensitizer moieties to imaging agent is from 2 to 1 to 4 to 1.21. The composition of where the photosensitizer is a HPPH claim 3 , ...

Подробнее
Номер записи: 61
15-08-2013 дата публикации

Amorphous Medicinal Fine Particles Produced By Pulsed Laser Ablation In Liquid And The Production Method Thereof

Номер: US20130209523A1
Автор: Andrius MARCINKEVICUS, Yuki Ichikawa
Принадлежит: IMRA America Inc

The present disclosure is directed to an in-liquid laser-based method for fabricating a solution of fine particles of amorphous solid medicinal compounds, a solution of fine particles of amorphous medicinal agents made with the method, and fine particles made with the method. By using a target solidified via a phase transition process to covert an initial crystalline structure into an amorphous solid, technical difficulties with handling a hydraulically-pressed target are overcome. The laser-based ablation process produces amorphous solid medicinal compound fine particles, which improves the bioavailability and solubility of the medicinal compound. The improvement results from a combination of: disordered crystalline structure and enlarged relative surface area by particle size reduction. The laser based method may be carried out with ultrashort pulsed laser systems, or with UV nanosecond lasers. Results obtained with an ultrashort near IR laser and a UV nanosecond laser show formation of amorphous solid curcumin fine particles.

Подробнее
Номер записи: 62
15-08-2013 дата публикации

PHEOPHORBIDE-alpha CONJUGATES AND THEIR USES

Номер: US20130210756A1
Автор: Kim Yong-Chul, KO Hyo Jin, YOU Hyun
Принадлежит: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY

The present invention relates to a pheophorbide-α conjugate or its salt, solvate or hydrate. The pheophorbide-α conjugate of the present invention exhibiting fluorescence upon its introduction into cells and degradation inhibits the survival of various cancer cells. Especially, the conjugate of pheophorbide-α and doxorubicin shows higher fluorescence intensity at lower pH (cancer environment). Therefore, the present composition for photodynamic therapy (PDT) of cancers is also very useful in detecting cancers. Interestingly, the anticancer effects of the present composition are dually exerted with help of both the photosensitizer and the anticancer drug of the present conjugates. 2. The pheophorbide-α conjugate according to claim 1 , wherein the pheophorbide-α conjugate further comprises a chemical linker linking the first compound and the second compound.3. The pheophorbide-α conjugate according to claim 2 , wherein the chemical linker is a hydroxycinnamoyl moiety or an aminobenzyloxycarbonyl moiety.5. A pharmaceutical composition for preventing or treating cancer claim 1 , comprising (a) a pharmaceutically effective amount of the pheophorbide-α conjugate according to ; and (b) a pharmaceutically acceptable carrier.6. The pharmaceutical composition according to claim 5 , wherein the cancer is selected from the group consisting of breast cancer claim 5 , cervical cancer claim 5 , lung cancer claim 5 , glioblastoma claim 5 , oral cancer claim 5 , pituitary adenoma claim 5 , glial tumor claim 5 , brain tumor claim 5 , nasopharyngeal tumor claim 5 , laryngeal cancer claim 5 , thymoma claim 5 , mesothelioma claim 5 , gastric cancer claim 5 , esophageal cancer claim 5 , colorectal cancer claim 5 , rectal cancer claim 5 , liver cancer claim 5 , pancreatic cancer claim 5 , pancreatic neuroendocrine tumor claim 5 , gallbladder cancer claim 5 , penis cancer claim 5 , ureter cancer claim 5 , renal cell carcinoma claim 5 , prostate cancer claim 5 , bladder cancer claim 5 , non ...

Подробнее
Номер записи: 63
15-08-2013 дата публикации

COMBINATION THERAPY USING RILUZOLE TO ENHANCE TUMOR SENSITIVITY TO IONIZING RADIATION

Номер: US20130210872A1
Автор: Chen Suzie, Goydos James S., Haffty Bruce G., Khan Atif Jalees
Принадлежит: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents. 1. A method of treating a tumor in a patient , said tumor comprising cells expressing a metabotropic glutamate receptor , said method comprising:(a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and(b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth.2. The method of claim 1 , wherein said tumor is a glioma.3. The method of claim 1 , wherein said tumor is a glioma and said metabotropic glutamate receptor is metabotropic glutamate receptor 3 (mGluR3; GRM3).4. The method of claim 1 , wherein said tumor is a melanoma.5. The method of claim 1 , wherein said tumor is a melanoma and said metabotropic glutamate receptor is metabotropic glutamate receptor 1 (mGluR1; GRM1).6. The method of claim 4 , wherein said melanoma is a metastatic melanoma to the brain.7. The method of claim 5 , wherein said melanoma is a metastatic melanoma to the brain.8. The method of claim 1 , wherein said tumor is a metastatic tumor.9. The method of claim 8 , wherein said tumor is a metastatic tumor to the brain.10. The method of claim 6 , said wherein the ionizing radiation comprises whole-brain irradiation.11. The method of claim 9 , said wherein the ionizing radiation comprises whole-brain irradiation.12. The method of claim 6 , wherein the ionizing radiation comprises fractionated whole-brain irradiation.13. The method of claim 9 , wherein the ionizing radiation comprises fractionated whole-brain irradiation.14. The method of claim 1 , wherein riluzole is administered in an amount of about 50 to about 200 mg/ ...

Подробнее
Номер записи: 64
15-08-2013 дата публикации

NOVEL SELENY-METHYLURACIL COMPOUNDS, RADIOSENSITIZER AND PHARMACEUTICAL COMPOSITION USING THEM

Номер: US20130211067A1
Автор: Greenberg Marc M., Hong In Seok, HONG Sung Hee
Принадлежит:

Provided are novel selenyl-methyluracil compounds and a pharmaceutical composition for enhancing the effect of radiation treatment. The composition contains at least one compound selected from the group consisting of the selenyl-methyluracil compounds or pharmaceutically acceptable salts thereof, as an active ingredient. 8. The pharmaceutical composition for treating cancer according to claim 7 , wherein the cancer is prostate cancer claim 7 , breast cancer claim 7 , brain tumor claim 7 , thyroid cancer claim 7 , pancreatic cancer claim 7 , pituitary cancer claim 7 , cervical cancer claim 7 , uterine cancer claim 7 , ovarian cancer claim 7 , esophageal cancer claim 7 , gastric cancer claim 7 , colon cancer claim 7 , rectal cancer claim 7 , liver cancer claim 7 , gallbladder cancer claim 7 , lung cancer claim 7 , oral cavity cancer claim 7 , skin cancer claim 7 , renal cancer claim 7 , leukemia claim 7 , lymphoma and myeloma. The present invention relates to novel selenyl-methyluracil compounds and a pharmaceutical composition for enhancing the effect of radiotherapy comprising the same.Methods for treating malignant tumors may be generally classified into surgical methods, chemotherapy and radiotherapy (radiation therapy). About 35% of all cancer patients in South-Korea and about 50% thereof in US receive some type of radiotherapy, at present, and the number of domestic patients who need to receive radiotherapy is increasing every year. Under this circumstance, the importance of radiotherapy in cancer treatment is presently increasing. Radiotherapy has been known as an essential treatment method for various types of cancer, however, it also has some problems such as resistance to radiation built in cancer cells, low efficiency against solid cancers, damages in normal tissue when high-dose of radiation is applied, or the like, resulting in lowering the efficiency in cancer treatment. For obtaining high anti-tumor effect, chemoradiotherapy, i.e., the combined therapy ...

Подробнее
Номер записи: 65
15-08-2013 дата публикации

HYPEROSMOTIC PREPARATIONS COMPRISING 5-AMINOLEVULINIC ACID OR DERIVATIVE AS PHOTOSENSITIZING AGENT

Номер: US20130211215A1
Автор: Godal Aslak, Heglund Inger Ferner, Klaveness Jo
Принадлежит: PHOTOCURE ASA

Provided herein are improved methods of photodynamic treatment and diagnosis of cancer and non-cancerous conditions in the gastrointestinal tract, e.g. in the colon, and in particular hyperosmotic enema preparations for use in such methods. The enema preparations comprise a photosensitizer which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative thereof, e.g. a 5-ALA ester, in combination with at least one hyperosmotic agent. The methods and preparations herein described are particularly suitable for use in photodynamic methods of treating and/or diagnosing colorectal cancer. 1. A hyperosmotic preparation comprising a photosensitizing agent and at least one hyperosmotic agent , wherein the photosensitizing agent comprises 5-ALA , a precursor or a derivative thereof.2. The hyperosmotic preparation of which comprises at least one hyperosmotic agent selected from the group consisting of salts claim 1 , sugars claim 1 , sugar alcohols claim 1 , glycerol claim 1 , polyols and combinations thereof.3. The hyperosmotic preparation of claim 2 , wherein the hyperosmotic agent comprises magnesium sulphate claim 2 , magnesium hydroxide claim 2 , magnesium citrate claim 2 , magnesium chloride claim 2 , sodium phosphate claim 2 , or any combination thereof.4. The hyperosmotic preparation of claim 2 , wherein the hyperosmotic agent comprises sorbitol claim 2 , mannitol claim 2 , lactitol claim 2 , xylitol claim 2 , lactulose claim 2 , fructose claim 2 , galactose claim 2 , lactose claim 2 , or any combination thereof.5. The hyperosmotic preparation of claim 2 , wherein the hyperosmotic agent comprises a polyether polyol claim 2 , preferably a polyethylene glycol (PEG) or polyethylenepolypropylene glycol (PPG).6. The hyperosmotic preparation of claim 1 , wherein the photosensitizing agent comprises a 5-ALA derivative or a pharmaceutically acceptable salt thereof.7. The hyperosmotic preparation of claim 1 , wherein the photosensitizing agent is a compound of formula I or ...

Подробнее
Номер записи: 66
22-08-2013 дата публикации

Kit providing multiple unmet therapeutic effects

Номер: US20130216574A1
Автор: James Liu
Принадлежит: Individual

The present invention discloses a unique kit for providing a combinational therapeutic product comprising a medical device and a pharmaceutical composition to treat mammal diseases. The medical device is to meet these unmet needs of cleansing out these harmful substances, such as viruses, multiple drug resistant bacteria, fungi, pollen, dusts, or excessive mucus. The pharmaceutical composition adds the required functions of anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, to have the added effect of the medical device. The method of using the combinational product is also disclosed. The new product can be used to prevent and treat a variety of diseases, such as common cold, drug resistant influenza, sinusitis, post nasal drip, virus-triggered asthma, or chronic obstructive pulmonary disease. In addition, the new kit and the process of use are safe and cost effective.

Подробнее
Номер записи: 67
29-08-2013 дата публикации

Methods and compositions for decreasing chronic pain

Номер: US20130225664A1
Автор: Alan Horsager, Benjamin C. Matteo, Christian Wentz, Douglas G. Ririe, Edward S. Boyden, James C. Eisenach, Kenneth Greenberg
Принадлежит: Individual

The present invention provides compositions and methods for the selective silencing of neurons in pain pathway by using a combination of inhibitory light-sensitive protein gene transfer and wavelength specific illumination.

Подробнее
Номер записи: 68
29-08-2013 дата публикации

ENHANCEMENT OF RADIATION THERAPY BY TARGETED HIGH-Z NANOPARTICLES

Номер: US20130225901A1
Автор: Diagaradjane Parmeswaran, Goodrich Glenn P., Krishnan Sunil, Payne J. Donald
Принадлежит: NANOSPECTRA BIOSCIENCES, INC.

A method for the design, manufacturing, and use of a high-Z particle to enhance the effects of ionizing radiation. In particular, the use of a targeting molecule to enable cellular uptake by the target cells (tumor cells or endothelial cells proximate to the tumor) will enhance the dose effect. 1. A method for enhancing the effects of radiation directed to a tissue or a population of cells comprising the steps of:administering to an animal an amount of high-Z particles, the high-Z particles comprising a targeting molecule with an affinity for a targeted tissue or a targeted population of cells and a high-Z element; andsubsequently irradiating the targeted tissue or targeted population of cells with ionizing radiation;wherein the high-Z particles are administered to the animal in an amount sufficient to achieve a concentration in the targeted tissue or the targeted population of cells of less than 0.05% metal by weight.2. The method of claim 1 , wherein the targeting molecule results in the internalization of the high-Z particles upon binding with the targeted tissue or the targeted population of cells.3. The method claim 1 , wherein the ionizing radiation is delivered in fractions over a period of time.4. The method of claim 1 , wherein the high-Z particles are administered to the animal one or more times.5. The method of claim 1 , wherein the targeted tissue or targeted population of cells is irradiated within the animal.6. The method of claim 1 , wherein the targeted tissue or targeted population of cells comprises cancer cells.7. The method of claim 6 , wherein the cancer cells are selected from the group consisting of: primary or metastatic colorectal cancer cells claim 6 , brain cancer cells claim 6 , lung cancer cells claim 6 , pancreatic cancer cells claim 6 , renal cancer cells claim 6 , breast cancer cells claim 6 , ovarian cancer cells claim 6 , uterine cancer cells claim 6 , endometrial cancer cells claim 6 , squamous cancer cells claim 6 , melanoma ...

Подробнее
Номер записи: 69
29-08-2013 дата публикации

ACNE THERAPEUTIC AGENT AND SEBUM SECERNENT INHIBITOR WHICH COMPRISE INDOLE-3-ALKYLCARBO XYLICACID, AND KITS FOR PHOTODYNAMIC THERAPY CONTAINING THE SAME

Номер: US20130226069A1
Автор: KIM Dong-seok, KIM So-young, KWON Sun-Bang
Принадлежит: WELSKIN CO., LTD.

The present invention relates to novel uses of indole-3-alkylcarboxylic acid and derivatives thereof as a photosensitizer for the treatment of acne or for the inhibition of sebum secretion. More particularly, the present invention is directed to a photosensitizer for photodynamic therapy, a photodynamic therapy kit and photodynamic therapeutic composition comprising thereof, which contain indole-3-alkylcarboxylic acid being activated by light. The light which activates indole-3-alkylcarboxylic acid of the present invention may be ultraviolet rays or visible lights, preferably blue light or green light. 124-. (canceled)26. The photodynamic acne therapy kit of claim 25 , wherein said light source irradiates ultraviolet ray of wavelength of 350 nm to 450 nm claim 25 , blue light of wavelength of 400 nm 500 nm claim 25 , or green light of wavelength of 500 nm 600 nm.27. The photodynamic acne therapy kit of claim 25 , wherein said light source is at least one of a light source for the in vitro irradiation selected from the group consisting of an ultrasound radiation emitter claim 25 , a light emitting diode claim 25 , a laser diode claim 25 , a dye laser claim 25 , a metal halide lamp claim 25 , a flashlamp claim 25 , a mechanically filtered fluorescent light source claim 25 , and a mechanically filtered incandescent or filamentous light source; and a laser fiber for photodynamic treatment by the in vivo radiation.28. The photodynamic acne therapy kit of claim 26 , wherein an intensity of a light irradiated by said light source is 1 J/cmto 100 J/cm.29. The photodynamic acne therapy kit of claim 28 , wherein a pulse duration time of the light irradiated by said light source is between 0.1 ms and 500 ms claim 28 , and the number of irradiation is between 1 and 100. The present invention relates to novel uses of indole-3-alkylcarboxylic acid and derivatives thereof as a photosensitizer for the treatment of acne or for the inhibition of sebum secretion. More particularly, ...

Подробнее
Номер записи: 70
05-09-2013 дата публикации

BONDING TISSUES AND CROSS-LINKING PROTEINS WITH NAPHTHALIMIDE COMPOUNDS

Номер: US20130230472A1
Автор: Judy Millard M., Kloster Kaia L., Matthews James L., Utecht Ronald E., Vaska Kevin J.
Принадлежит: Alumend, LLC

Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin. 135.-. (canceled)36. A method for local delivery of a functional compound to skin comprising:contacting a compound having the formula D-B—F to skin; andsubjecting the compound to an activating agent wherein the compound is cleaved so that a compound B—F is tethered to the skin; andwherein D is a naphthalimide compound, B is a biomolecule, and F is the functional compound.38. The method of claim 36 , wherein B is a biomolecule selected from the group consisting of chitosan claim 36 , protein claim 36 , hydrolyzed protein claim 36 , and carbohydrates.39. The method of claim 36 , wherein the functional compound is selected from the group consisting of a pharmacological agent claim 36 , a skin care material claim 36 , a sunscreen claim 36 , and a cosmetic.40. The method of claim 36 , wherein the functional compound comprises at least one of sulfonic acid functional groups claim 36 , alcohol functional groups claim 36 , and amine functional groups.41. The method of claim 40 , wherein the functional compound comprising sulfonic acid functional groups is chosen from phenylbenzimidazole sulfonic acid and sulisobenzone.42. The method of claim 40 , wherein ...

Подробнее
Номер записи: 71
19-09-2013 дата публикации

RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER

Номер: US20130243741A1
Автор: Basel Matthew T., Bossmann Stefan H., Shrestha Tej B., Troyer Deryl L., Wang Hongwang
Принадлежит: Kansas State University Research Foundation

A method for photodynamic therapy treatment of cancerous cells and tissue is provided. The method comprises administering tumor-trophic cells expressing a luminescent protein to a subject. A photosensitizing agent is then separately administered to the subject, followed by an optional iron chelator. On the day of treatment, a luminogenic substrate corresponding to the luminescent protein is administered to the subject. The substrate reacts with the luminescent protein in the vicinity of the cancerous tissue to produce light which activates the photosensitizing agent resulting in the selective destruction of the cancerous tissue. 1. A method for photodynamic therapy of cancerous tissue comprising:administering to a subject a therapeutically effective amount of tumor-trophic cells comprising a nucleic acid encoding for a luminescent protein;administering a photosensitizing agent to said subject, wherein said photosensitizing agent is administered separately from said cells;optionally administering an iron chelator to said subject; andadministering a luminogenic substrate corresponding to said luminescent protein to said subject;wherein said substrate reacts with said luminescent protein to produce light, said light activating the photosensitizing agent which results in the damage and destruction of the cancerous tissue.2. The method of claim 1 , wherein said cells are selected from the group consisting of mammalian stem cells claim 1 , monocytes claim 1 , neutrophils claim 1 , and combinations thereof.3. (canceled)4. The method of claim 1 , wherein said cells are administered via intravenous injection claim 1 , intraperitoneal injection claim 1 , intramuscular injection claim 1 , intratumoral injection claim 1 , intraarterial injection claim 1 , inhalation claim 1 , or a combination thereof.5. The method of claim 1 , wherein about 500 claim 1 ,000 to about 200 million cells are administered to said subject.6. The method of claim 1 , wherein said cells secrete said ...

Подробнее
Номер записи: 72
19-09-2013 дата публикации

Magnetic Nanoparticle Formulations, Methods for Making Such Formulations, and Methods for their Use

Номер: US20130245357A1
Автор: Chauhan Subhash, Jaggi Meena, Yallapu Murali Mohan
Принадлежит: SANFORD RESEARCH/USD, a nonprofit Corporation Organized Under South Dakota Law

The present invention provides derivatized magnetic nanoparticles, methods for making such nanoparticles, and methods for their use. 1. A magnetic nanoparticle (MNP) comprising(a) a core MNP;(b) first layer of cyclodextrin over the core MNP; and(c) a second layer of a pluronic polymer over the cyclodextrin layer.2. The MNP of claim 1 , wherein the core MNP comprises iron claim 1 , nickel claim 1 , cobalt claim 1 , or derivatives thereof.3. The MNP of claim 1 , wherein the core MNP comprises iron oxide.4. The MNP of claim 1 , wherein the core MNP is between about 5 nm and about 30 nm in diameter.5. An MNP cluster claim 1 , comprising a plurality of MNPs according to claim 1 , wherein the MNP cluster is between about 50 nm and about 200 nm in diameter.6. The MNP cluster of claim 5 , wherein the MNP cluster is between about 75 nm and about 150 nm in diameter.7. The MNP of claim 1 , wherein the cyclodextrin is selected from the group consisting of α-cyclodextrin claim 1 , β-cyclodextrin claim 1 , and γ-cyclodextrin claim 1 , and derivatives thereof.8. The MNP of claim 1 , wherein the cyclodextrin comprises β-cyclodextrin claim 1 , or derivatives thereof.9. The MNP of claim 1 , wherein the MNP comprises a molar ratio of between about 1:40 to 1:300 cyclodextrin:metal ion in the core MNP.10. The MNP of claim 1 , wherein the pluronic polymer comprises an ethylene oxide/propylene oxide block copolymer.11. The MNP of claim 1 , wherein the MNP comprises a molar ratio of between about 1:1 and 1:10 cyclodextrin:pluronic polymer.12. The MNP of claim 1 , wherein the MNP further comprises a therapeutic loaded into or onto the MNP claim 1 , a cell-targeting compound bound to the MNP claim 1 , and/or a photosensitizer loaded into or onto the MNP.1315-. (canceled)16. A method for making magnetic nanoparticles (MNPs) claim 1 , comprising(a) precipitating metal salts in the presence of ammonia to obtain metal oxide core nanoparticles; and (i) cyclodextrin; and', '(ii) a pluronic polymer ...

Подробнее
Номер записи: 73
19-09-2013 дата публикации

PHOTOACTIVE VITAMIN NANOPARTICLES FOR THE TREATMENT OF CHRONIC WOUNDS

Номер: US20130245598A1
Автор: Fu-Giles Patty
Принадлежит:

The preparation and use of photosensitizer-containing nanoparticles including photoactive vitamin-containing nanoparticles as photodynamic antimicrobial agents are disclosed for tissue repair including the treatment of chronic wounds. 1. A composition for the treatment of chronic wounds comprising nanoparticles formed of a copolymer , the nanoparticles containing a therapeutically effective amount of at least one photosensitizer whereby irradiation of the photosensitizer provides for tissue repair.2. The composition according to wherein the copolymer comprises polyoxyethylene and polyoxypropylene.3. The composition according to wherein the copolymer is selected from the group consisting of poloxamers claim 1 , polysorbates claim 1 , polyethylene glycols claim 1 , polyethylene glycol ethers claim 1 , phosphocholines claim 1 , polyvinyl alcohols claim 1 , poly(lactic-co-glycolic acids) and derivatives claim 1 , mixtures and blends thereof.4. The composition according to wherein the photosensitizer is selected from the group consisting of riboflavin (vitamin B) claim 1 , cobalamin (vitamin B) claim 1 , phylloquinone (vitamin K) claim 1 , menaquinone (vitamin K) claim 1 , and a phthalocyanine.5. The composition according to wherein the phthalocyanine is selected from the group consisting of copper phthalocyanine claim 4 , aluminum disulfonated phthalocyanine and zinc phthalocyanine.6. The composition according to wherein the composition is in a form suitable for topical administration.7. The composition according to wherein the composition is in a form selected from the group consisting of liquid claim 1 , lotion claim 1 , cream or ointment.8. A composition for the treatment of chronic wounds comprising nanoparticles formed of a copolymer claim 1 , the nanoparticles containing a therapeutically effective amount of at least one photoactive vitamin whereby irradiation of the photoactive vitamin provides for tissue repair.9. The composition according to wherein the ...

Подробнее
Номер записи: 74
03-10-2013 дата публикации

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AN OCULAR DISEASE IN A SUBJECT

Номер: US20130261535A1
Автор: Behar-Cohen Francine
Принадлежит: Institut National de la Sante et de la Recherche Medicale (INSERM)

A method of treating an ocular disease in a subject includes delivering a pharmaceutical composition into a ciliary muscle of the subject and inducing transfection of the therapeutic nucleic acid into the ciliary muscle by exposing the pharmaceutical composition to ultrasound. The pharmaceutical composition comprises echo-contrast agent microbubbles and a therapeutic nucleic acid. 18-. (canceled)9. A method of treating an ocular disease in a subject , comprising:delivering a pharmaceutical composition into a ciliary muscle of the subject, the pharmaceutical composition comprising echo-contrast agent microbubbles and a therapeutic nucleic acid; andinducing transfection of the therapeutic nucleic acid into the ciliary muscle by exposing the pharmaceutical composition to ultrasound.10. The method of claim 9 , wherein the therapeutic nucleic acid is a deoxyribonucleic acid (DNA) molecule or a ribonucleic acid (RNA) molecule.11. The method of claim 9 , wherein the therapeutic nucleic acid is in a vector.12. The method of claim 11 , wherein the vector is a plasmid.13. The method of claim 9 , wherein the therapeutic nucleic acid encodes a polypeptide selected from the group consisting of enzymes claim 9 , blood derivatives claim 9 , hormones claim 9 , lymphokines claim 9 , cytokines claim 9 , chemokines claim 9 , anti-inflammatory factors claim 9 , growth factors claim 9 , trophic factors claim 9 , neurotrophic factors claim 9 , hematopoietic factors claim 9 , angiogenic factors claim 9 , anti-angiogenic factors claim 9 , metalloproteinase inhibitors claim 9 , apoptosis regulators claim 9 , coagulation factors claim 9 , receptors thereof claim 9 , peptides that are an agonist or antagonist of a receptor claim 9 , peptides that are an agonist or antagonist of an adhesion protein claim 9 , antigens claim 9 , antibodies claim 9 , fragments and derivatives thereof and other polypeptide constituents of a cell.14. The method of claim 9 , wherein the microbubbles comprise a shell ...

Подробнее
Номер записи: 75
03-10-2013 дата публикации

Method, Device and System for Targetted Cell Lysis

Номер: US20130261683A1
Автор: Dodgson John Robert, Soikum Soiwisa, Thomsen Lars
Принадлежит: GIANTCODE CORPORATION PTE LTD

A method, device and system employs particles, such as nanoparticles, and an electric or electro-magnetic field, to cause cell death in target cells by non-thermal means. The method of causing targeted cell death comprises the steps of: introducing a particle to the interior of a target cell and exposing the target cell to a transient electromagnetic field for a sufficient time interval in order to cause cell death. The invention overcomes problems associated with similar methods as a result of the fact that a smaller electric field is applied because the particle enhances the effect of the electric field in its immediate vicinity, so reducing the field strength needed to achieve cell lysis and thereby reducing the risk of damage to healthy cells that may be in its vicinity. Apparatus for performing the method; as well as techniques of delivering particles and for producing particles are also described. 1. A method of causing targeted cell death by a non-thermal mechanism comprising:introducing a particle to an interior of a target cell; andexposing said target cell to an electric field for a sufficient time interval to cause cell death.2. A method of causing targeted cell death by a non-thermal mechanism according to claim 1 , wherein:said particle in said target cell, and said electric field, are selected so as to cause irreversible electroporation of said target cell.3. A method of causing targeted cell death by a non-thermal mechanism according to claim 1 , further comprising:adhering a second particle on, or adjacent, an exterior surface of said target cell.4. A method of causing targeted cell death by a non-thermal mechanism claim 1 , comprising:introducing at least two particles outside a target cell; andexposing said target cell to a transient electromagnetic field for a time interval sufficient to cause cell death;whereby said at least two particles act co-operatively to cause said cell death.5. A method of causing targeted cell death by a non-thermal ...

Подробнее
Номер записи: 76
10-10-2013 дата публикации

PROLYL HYDROXYLASE INHIBITORS AS RADIATION MITIGATORS AND RADIATION PROTECTORS

Номер: US20130267594A1
Автор: Price Brendan D., SUN Yingli
Принадлежит: Dana-Farber Cancer Institute Inc.

A method to inhibit tissue injury in a subject resulting from exposure to radiation is provided. The method involves administering to the subject a prolyl hydroxylase (PH) inhibitor in an amount effective to inhibit tissue injury caused by radiation exposure of the subject. The invention also involves a screen for PH inhibitors that inhibit tissue damage resulting from exposure to radiation. Compounds that inhibit the enzymatic activity of PHs are tested for their ability to protect against radiation damage. 1. A method to inhibit tissue injury in a subject resulting from exposure to radiation , the method comprising:administering to the subject in need thereof a prolyl hydroxylase (PH) inhibitor in an amount effective to inhibit tissue injury caused by radiation exposure of the subject, wherein the tissue is non-cancerous.2. The method of claim 1 , wherein the radiation exposure results from radiation therapy.3. The method of claim 1 , wherein the inhibitor is administered between 1 day before and 3 days after exposure of the subject to the radiation exposure.4. The method of claim 1 , wherein the inhibitor is administered after the radiation exposure claim 1 , but within 48 hours of the radiation exposure.5. The method of claim 1 , wherein the inhibitor is a non-specific PH inhibitor.6. The method of claim 1 , wherein the inhibitor is an inhibitor of HIF1α-prolyl hydroxylase or of histone lysine demethylase (KDM).7. The method of claim 1 , wherein the inhibitor is selected from the group consisting of: dimethyloxalylglycine (DMOG) claim 1 , N-oxalylglycine (NOG) claim 1 , desferrioxamine (DFO) claim 1 , FG-4383 claim 1 , F-0041 claim 1 , FG-2216 claim 1 , FG-4592 claim 1 , S956711 claim 1 , ethyl-3 claim 1 ,4 dihydroxy-benzoate (EDHB) claim 1 , TM6089 claim 1 , TM655 claim 1 , TM6008 and 8-hydroxyquinoline derivatives.8. The method of claim 1 , wherein the inhibitor is administered parenterally.9. The method of claim 1 , wherein the inhibitor is administered ...

Подробнее
Номер записи: 77
24-10-2013 дата публикации

BIOPHOTONIC COMPOSITIONS AND METHODS FOR PROVIDING BIOPHOTONIC TREATMENT

Номер: US20130281913A1
Автор: Loupis Nikolaos, Piergallini Remigio, Rastogi Shipra
Принадлежит:

The present disclosure provides biophotonic topical compositions and methods useful in phototherapy. In particular, the biophotonic topical compositions of the present disclosure are substantially resistant to leaching such that very low amounts of chromophore(s) present in the biophotonic composition leach out of the composition. The biophotonic compositions and the methods of the present disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and various skin disorders. 1. A method for promoting wound healing , comprising:applying a biophotonic composition to a wound, wherein the biophotonic composition comprises at least a first chromophore and a gelling agent; andilluminating said biophotonic composition with light having a wavelength that overlaps with an absorption spectrum of the first chromophore;wherein the gelling agent renders the biophotonic composition substantially resistant to leaching such that less than 15% of the total chromophore amount leaches out of the biophotonic composition into tissue during treatment.2. A method for biophotonic treatment of a skin disorder , comprising:applying a biophotonic composition to a target skin tissue afflicted with the skin disorder, wherein the biophotonic composition comprises a first chromophore and a gelling agent; andilluminating said biophotonic composition with light having a wavelength that overlaps with an absorption spectrum of the first chromophore;wherein the gelling agent renders the biophotonic composition substantially resistant to leaching such that less than 15% of the total chromophore amount leaches out of the biophotonic composition into tissue during treatment.3. A method for biophotonic treatment of acne , comprising:applying a biophotonic composition to target tissue wherein the biophotonic composition comprises a first chromophore and a gelling agent, wherein the tissue is an acne lesion or an acne scar; andilluminating said biophotonic composition ...

Подробнее
Номер записи: 78
24-10-2013 дата публикации

SONOSENSITIVE NANOPARTICLES

Номер: US20130281916A1
Автор: Arora Manish, Constantin-Cassios Coussios, Molinari Michael Bernard, Schiffter-Weinle Heiko Alexander, Wagstaffe Sarah Jayne
Принадлежит: lsis Innovation Limited

A method of delivering a therapeutic substance to tissue comprises delivering the therapeutic substance and nanoparticles to the tissue, the nanoparticles having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm, and insonating the tissue with pressure waves. Corresponding particles, and associated methods of controlling and imaging the treatment and delivery are also disclosed. 1. A nanoparticle for inducing cavitation in a medium under insonation , the nanoparticle having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm.2. A nanoparticle for the treatment of cancer in a body , the nanoparticle having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm , whereby the nanoparticle is arranged to enhance cavitation in the body when the body is insonated with pressure waves.3. A system for treating cancerous tissue , the system comprising a source of pressure waves and nanoparticles for delivery to the tissue , the nanoparticles having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm , whereby the nanoparticles are arranged to enhance cavitation in the tissue when the tissue is insonated with pressure waves from the source.4. A method of controlling cavitation in tissue , the method comprising delivering nanoparticles to the tissue , the nanoparticles having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm , and insonating the tissue with pressure waves.5. A method of imaging an object , the method comprising delivering nanoparticles to the object , the nanoparticles having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm , and insonating the object with pressure waves such that the nanoparticles induce cavitation in the ...

Подробнее
Номер записи: 79
31-10-2013 дата публикации

Pharmaceutical Compositions for Topical Delivery of Photosensitizers and Uses Thereof

Номер: US20130289089A1
Автор: Hunt David W.C., Morris Jerome A., Utkhede Deepank
Принадлежит:

The invention includes and provides compositions comprising photosensitizing agents, in particular lemuteporfin, and their use in photo-dynamic therapy for the treatment of dermatological conditions. 2. The composition of claim 1 , wherein said photosensitizer is present at a concentration in the range of about 0.01% to about 1.0%.3. The composition of claim 2 , wherein said photosensitizer is present at a concentration in the range of about 0.025% to about 0.5%.4. The composition of claim 3 , wherein said photosensitizer is present at a concentration in the range of about 0.1% to about 0.2%.5. The composition of claim 1 , wherein said excipient component comprises benzyl alcohol at a concentration in the range of about 1% to about 20%.6. The composition of claim 5 , wherein said benzyl alcohol concentration is about 10%.7. The composition of claim 1 , wherein said excipient component comprises diethylene glycol monoethyl ether (DGME) at a concentration in the range of about 5% to about 50%.8. The composition of claim 7 , wherein said excipient DGME concentration is in the range of about 15% to about 35%.9. The composition of claim 1 , wherein said excipient component comprises isopropyl alcohol at a concentration in the range of 40 to 70%.10. The composition of claim 1 , wherein said photosensitizer is a green porphyrin.11. The composition of claim 10 , wherein said green poprhyrin is lemuteporfin.12. A topical formulation effective for localizing a photosensitizer to a sebaceous gland comprising:(a) a photosensitizing component comprising a photosensitizer; and associated therewith but separate therefrom,(b) an excipient component;wherein said photosensitizer is present in an amount sufficient to form, on mixing, a supersaturated solution thereof once components (a) and (b) are mixed.13. A topical formulation of for use in a method of treating acne in a subject in need thereof claim 1 , comprising applying a therapeutically effective amount of said composition to ...

Подробнее
Номер записи: 80
31-10-2013 дата публикации

TARGETED AND LIGHT-ACTIVATED CYTOSOLIC DRUG DELIVERY

Номер: US20130289520A1
Автор: Clapham David E., Febvay Sebastien, Marini Davide Maurizio
Принадлежит:

The present invention provides methods and compositions for highly precise spatial and temporal control over cytosolic delivery of compounds, in particular, those compounds that would otherwise be cell-impermeable. Among other things, the present invention provides a composition for targeted drug delivery comprising a nanoparticle, a targeting moiety specific for a cell type of interest, a light-activated drug delivery system, wherein the nanoparticles are associated with the targeting moiety and the light-activated drug delivery system. 1. A composition for targeted drug delivery comprisingnanoparticles;a targeting moiety specific for a cell type of interest;a light-activated drug delivery system;wherein the nanoparticles are associated with the targeting moiety and the light-activated drug delivery system.2. The composition of claim 1 , wherein the nanoparticles are of mesoporous silicate materials.3. The composition of claim 1 , wherein the nanoparticles have size less than 200 nm in diameter.48-. (canceled)9. The composition of claim 1 , wherein the nanoparticles are PEGylated.10. The composition of claim 1 , wherein the targeting moiety comprises an antibody or fragment thereof.11. The composition of claim 10 , wherein the antibody or fragment thereof is tumor-specific.12. (canceled)13. The composition of claim 10 , wherein the antibody or fragment thereof is an antibody specific to a multidrug resistance transporter.14. The composition of claim 13 , wherein the multidrug resistance transporter is MDR1 (also known as P-glycoprotein) claim 13 , or MRP1.15. The composition of claim 1 , wherein the targeting moiety is conjugated to the nanoparticles.16. The composition of claim 1 , wherein the light-activated drug delivery system comprises a photosensitizer and a therapeutic agent.17. The composition of claim 16 , wherein the photosensitizer is capable of causing permeabilisation of endosome membranes upon light activation.18. The composition of claim 17 , wherein ...

Подробнее
Номер записи: 81
07-11-2013 дата публикации

RHODAMINE DERIVATIVES FOR PHOTODYNAMIC DIAGNOSIS AND TREATMENT

Номер: US20130295059A1
Автор: Guimond Martin, Molfino Nestor, ROY DENIS-CLAUDE, Villeneuve Luc
Принадлежит:

Compositions and methods for reducing or preventing graft-versus-host disease associated with allogeneic stem cell transplantation are described. A method includes harvesting hematopoietic cells from a patient with an immunologic disorder and harvesting hematopoietic cells from a donor. The harvested hemaptopoietic cells from the patient and the donor are mixed ex vivo for a period of time sufficient to activate lymphocytes within the hematopoietic cells harvested from the donor such that an immune reaction occurs and an activated portion and an unactivated portion is produced. A rhodamine B derivative is then added to the mixture of cells and the mixture is irradiated at a suitable wavelength and intensity for the selective destruction and/or inactivation of the activated portion without substantially affecting the unactivated portion or causing systemic toxicity in said patient. The irradiated cells are then infused into the patient. 1a) harvesting hematopoietic cells from a patient with an immunologic disorder;b) harvesting hematopoietic cells from a donor;c) mixing the cells of step a) with the cells of step b) ex vivo for a period of time sufficient to activate lymphocytes within the hematopoietic cells harvested from said donor such that an immune reaction occurs, wherein an activated portion and an unactivated portion is produced;d) adding to the mixture of cells of step c) ex vivo a therapeutic amount of a rhodamine derivative according to formula (I):. A method of reducing or preventing graft-versus-host disease associated with allogeneic stem cell transplantation, which comprises the steps of:e) irradiating the mixture of cells of step d) ex vivo with a suitable wavelength and intensity for the selective destruction and/or inactivation of the activated portion without substantially affecting the unactivated portion or causing systemic toxicity in said patient; andf) infusing the mixture of cells of step e) into the patient. This is a continuation of U.S. ...

Подробнее
Номер записи: 82
07-11-2013 дата публикации

ORGANIC ELECTROLUMINESCENT DEVICE

Номер: US20130296288A1
Автор: Pan Junyou, Stoessel Philipp
Принадлежит: Merck Patent GmBH

The present invention relates to a salt in which at least one cation and at least one anion is in each case an emitter compound or a dye compound, characterised in that at least one of the emitter compounds is a fluorescent emitter compound. In addition, the present invention also relates to a process for the preparation of the salt according to the invention, to the use of the salt in an electronic device, and to a formulation and an electronic device which comprises the salt. 122-. (canceled)23. A salt in which both at least one cation and also at least one anion is an emitter compound or a dye compound , where one emitter compound is a fluorescent emitter compound.24. The salt according to claim 23 , in which all emitter compounds are non-metal compounds.25. The salt according to claim 23 , in which all emitter compounds are fluorescent emitter compounds.26. The salt according to claim 23 , in which either the cation or the anion is a metal-complex dye compound claim 23 , and the respective other is a fluorescent emitter compound.27. The salt according to claim 23 , which is in the form [E][E] claim 23 , where [E]is an emitter compound having the charge +m and [E]is an emitter compound having the charge −m claim 23 , where m is equal to 1 or 2.28. The salt according to claim 27 , in which [E]is a phosphorescent emitter compound Tand [E]is a fluorescent emitter compound S-m.29. The salt according to claim 28 , in which the phosphorescent emitter compound is a metal-ligand coordination compound.30. The salt according to claim 27 , in which [E]and [E]are fluorescent emitter compounds Sand S.31. The salt according to claim 27 , in which m is equal to 1.32. The salt according to claim 23 , which is in the form [E][E][E] claim 23 , where [E]is an emitter compound having the charge p and [E]and [E]are emitter compounds having the charge k claim 23 , where and p+2k=0 claim 23 , and k equals to ±1 or ±2.33. The salt according to claim 32 , in which [E]and/or [E]is (are) ( ...

Подробнее
Номер записи: 83
14-11-2013 дата публикации

Carrier-Linked Magnetic Nanoparticle Drug Delivery Composition and Method of Use

Номер: US20130302408A1
Автор: WEAVER John B.
Принадлежит: Trustees of Dartmouth College

The present invention is a targeted drug delivery composition composed of carrier-linked magnetic nanoparticles. Using an alternating magnetic field, nanoparticles bound to a targeted cell are selectively ruptured thereby releasing therapeutic agents at the desired site of action. 16-. (canceled)7. A drug delivery composition comprising(a) a first carrier-linked magnetic nanoparticle containing a prodrug; and(b) a second carrier-linked magnetic nanoparticle containing an enzyme for activating the prodrug, wherein one or both of the carrier-linked magnetic nanoparticles of (a) and (b) comprises a targeting moiety and wherein the first or second carrier is a liposome.8. A method for providing a therapeutic agent to a subject comprising administering to a subject in need thereof a carrier-linked magnetic nanoparticle containing a therapeutic agent , and applying an alternating magnetic field to the subject thereby providing the therapeutic agent to the subject.9. The method of claim 8 , wherein the therapeutic agent is a prodrug.10. The method of claim 8 , further comprising administering a carrier-linked magnetic nanoparticle containing a moiety for activating the prodrug.11. The method of claim 8 , wherein the carrier is a liposome. The patent application claims the benefit of priority from U.S. Provisional Application Ser. No. 61/422,285 filed Dec. 13, 2010, the content of which is incorporated herein by reference in its entirety.This invention was made with government support under contract number CA151662 awarded by the National Institutes of Health. The government has certain rights in the invention.Magnetic nanoparticles are particles composed of ferrite (e.g., FeOand FeO) and have been suggested for use in delivering drugs or physiologically active materials with or without coatings such as dextran, lipid, liposome, polymer or the like (JP 2002-128523; JP 9-110722; U.S. Pat. No. 7,560,097; 7,731,648). However, the use of magnetic nanoparticles in the medical ...

Подробнее
Номер записи: 84
14-11-2013 дата публикации

PERYLENEQUINONE DERIVATIVES AND USES THEREOF

Номер: US20130304089A1
Автор: Naicker Selvaraj, Sharma Sanjay K., Woo Thomas
Принадлежит:

The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders. 196-. (canceled)98. The compound of claim 97 , wherein Ris a hydrogen atom claim 97 , Ris a hydrogen atom claim 97 , T is —CH— and p has a value of 4 claim 97 , so that ring A is a six-membered ring.99. The compound of claim 97 , wherein each Ris a methyl group.100. The compound of claim 97 , wherein R claim 97 , R claim 97 , Rand Rrepresent a hydrogen atom.101. A composition comprising a compound as defined in claim 97 , and a pharmaceutically acceptable carrier.102. A method for body hair removal comprising{'claim-ref': {'@idref': 'CLM-00097', 'claim 97'}, 'a) administering a compound as defined in to a subject; and'}b) irradiating a surface of the body of said subject from which hair is to be removed with a light having a wavelength suitable for activating said compound.104. A process as claimed in claim 103 , wherein step (a) is carried out at a temperature of about 40 to about 100° C.105. A process as claimed in claim 103 , wherein said step (a) is carried out at a temperature of about 55 to about 59° C. The present invention relates to the field of medicinal chemistry. In particular, it relates to perylenequinone derivatives. Such compounds can be used in photodynamic therapy or as photosensitizers. These compounds, which are useful as therapeutic agents, can also be used for treating various hyperproliferative disorders.Photodynamic therapy (PDT) is a treatment modality using light of an appropriate wavelength to activate a photosensitizer in the presence of oxygen, which generates active oxygen species of ...

Подробнее
Номер записи: 85
21-11-2013 дата публикации

METHODS TO REGULATE POLARIZATION AND ENHANCE FUNCTION OF CELLS

Номер: US20130309278A1
Автор: PEYMAN Gholam A.
Принадлежит:

Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization and enhance function of such cells. The cells include retinal and other excitable cells, and normally non-excitable cells in proximity to partially or wholly non-functional excitable cells. 1. A method of delivering quantum dots to an anatomical and/or physiological site comprising providing quantum dots in an injectable fluid where the quantum dots are included in bio absorbable or non-absorbable but biocompatible polymers , and/or implanting the quantum dots as coated fibers , tubes , or two or three dimensional structures to fit any location and at any desirable length and size.2. The method of where a plurality of quantum dot nanoparticles or nanowires comprises a polymer or coats a surface of a polymer.3. The method of where a plurality of quantum dots are provided on at least one of a fiber optic two dimensional stripe or branching structure claim 1 , or a nano wire conjugated with a stimulatory biomolecule.4. The method of where the stimulatory biomolecule is a channel ion activator.5. The method of where claim 1 , upon activation of the quantum dots claim 1 , a plurality of areas in an organ to which the quantum dots are provided are simultaneously stimulated.6. The method of where activation is by at least one of a fiber light guide claim 5 , a tubular light guide claim 5 , a substantially two-dimensional light guide claim 5 , or a three-dimensional-branched light guide.7. The method of where the quantum dots are on the surface of the light guide.8. The method of further comprising administering a therapeutic agent to the site in association with the plurality of particles to ameliorate the condition.9. A method to create an analog of an excitable biological cell comprisingtaking from a tissue a target cell having a suboptimal responsive to a ...

Подробнее
Номер записи: 86
21-11-2013 дата публикации

SPINNING NANOWIRES AND METHOD FOR INDUCING CELL ERADICATION USING SAME

Номер: US20130309280A1
Автор: CHOI Sung Hoi, Kim Young Keun, PARK Jung Rae
Принадлежит: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

The present invention provides a cell eradication method and a cell eradication principle for necrotizing a cell by agitating a cell using a physical turning force from the impression of an AC magnetic field, after preparing a magnetic nanowire having a dipole and introducing the magnetic nanowire into a cell. Therefore, the composition for inducing cell eradication of the present invention, when applied to a cell that is requested to be removed such as a cancer cell, can eradicate the cell by applying a physical impact through the rotation of the nanowire introduced inside the cell. Additionally, the heat generated from induced current from the magnetic field impression can add an effect of thermotherapy, and also, attaching a drug to the surface of the nanowire enhances the treatment effects. 113-. (canceled)14. A method for inducing cell eradication , comprising:administering a composition comprising a nanowire having a dipole to a subject, and impressing a magnetic field in the subject.15. The method according to claim 14 , wherein the nanowire is a metal nanowire claim 14 , a magnet nanowire claim 14 , or a metal/magnet composite nanowire.16. The method according to claim 15 , wherein the metal is gold claim 15 , platinum claim 15 , palladium claim 15 , copper claim 15 , aluminum claim 15 , or alloys thereof.17. The method according to claim 15 , wherein the magnet is nickel claim 15 , cobalt claim 15 , iron claim 15 , gadolinium claim 15 , alloys thereof claim 15 , or oxides thereof.18. The method according to claim 14 , wherein the nanowire has a diameter of from 1 to 1000 nm and a length of from 1 to 100 μm.19. The method according to claim 14 , wherein electric or magnetic dipoles are formed in both ends of the nanowire.20. The method according to claim 14 , wherein the nanowire is a barcode type nanowire having a multilayer structure.21. The method according to claim 14 , wherein the nanowire is a nanowire having a core-shell structure.22. The method ...

Подробнее
Номер записи: 87
05-12-2013 дата публикации

COMPOSITIONS AND METHODS COMPRISING ENERGY ABSORBING MATERIALS FOR FOLLICULAR DELIVERY

Номер: US20130323305A1
Автор: Anderson Richard Rox, Blomgren Richard, Doukas-Anderson Apostolos G., Farinelli William A., Paithankar Dilip
Принадлежит: The General Hospital Corporation

The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets. 1. A method of treating or ameliorating a follicular skin disease in a subject , the method comprising:a) topically applying a formulation comprising sub-micron particles comprising a light absorbing material to the subject's skin;b) facilitating delivery of said material into a hair follicle, sebaceous gland, sebaceous gland duct, or infundibulum of the skin by mechanical agitation, acoustic vibration, ultrasound, alternating suction and pressure, or microjets; andc) exposing said sub-micron particles to energy activation, thereby treating or ameliorating the follicular skin disease in the subject.2. The method of wherein delivery of said material into the hair follicle is facilitated by ultrasound-created microjets within the formulation.3. The method of claim 2 , wherein exposing said sub-micron particles to energy activation comprises irradiating said sub-micron particle with light claim 2 , thereby heating the particle.4. The method of wherein the sub-micron particles are within a sebaceous gland during irradiation.5. The method of the sub-micron particles are substantially completely within the sebaceous gland during irradiation.6. The method of wherein the sub-micron particles are within a sebaceous gland duct during irradiation.7. The method of wherein the sub-micron particles are substantially completely within the sebaceous gland duct during irradiation.8. The method of wherein the sub-micron particles are within an infundibulum involved in the follicular skin disease.9. The method of claim 3 , wherein a light absorbing material in ...

Подробнее
Номер записи: 88
05-12-2013 дата публикации

Lighting Systems and Methods of Using Lighting Systems for In Vitro Potency Assay for Photofrin

Номер: US20130323779A1
Автор: Michael S. Roberts
Принадлежит: Pinnacle Biologics Inc

Presently disclosed is a lighting system and methods of using the lighting system for in vitro potency assay for photofrin. The lighting system includes a lamp housing, a first lens, an infrared absorbing filter, an optical filter, and a second lens. The lamp housing includes a lamp and a light-port. In operation, broad spectrum light from the lamp exits the lamp housing by passing through the light-port. The first lens then collimates the broad spectrum light that exits the lamp housing through the light-port. The infrared absorbing filter then passes a first portion of the collimated broad spectrum light to the optical filter and absorbs infrared light of the broad spectrum light. The optical filter then passes a second portion of the collimated broad spectrum light to the second lens. The second lens then disperses the second portion of the collimated light to provide uniform irradiation of a cell culture plate. A method of using the lighting system for studying a photosensitizer is also disclosed.

Подробнее
Номер записи: 89
12-12-2013 дата публикации

ULTRASOUND-TRIGGERABLE AGENTS FOR TISSUE ENGINEERING

Номер: US20130330389A1
Автор: Fabiilli Mario L., Martin-Saavedra Francisco, Padilla Frederic, Wilson Christopher
Принадлежит: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

The present invention is directed to compositions and methods for delivering a tissue scaffold comprising ultrasound-triggerable agents to an individual. 1. A device comprising:(a) a tissue scaffold;(b) an emulsion that comprises a perfluorocarbon (PFC) droplet comprising a therapeutic agent in the interior thereof, the PFC having a mean droplet diameter that is at least about 20 micrometers (μm), andthe emulsion having a volume fraction in the tissue scaffold of at least about 1% volume: volume.2. A device comprising:(a) a tissue scaffold; and(b) an emulsion comprising a first population of perfluorocarbon (PFC) droplets comprising a therapeutic agent in the interior thereof, said first population of PFC droplets having the property of vaporizing at a first ultrasound frequency and/or acoustic pressure threshold.3. The device of claim 2 , further comprising a second population of PFC droplets claim 2 , said second population of PFC droplets having the property of vaporizing at a second ultrasound frequency and/or acoustic pressure threshold that is different than the first ultrasound frequency and/or acoustic pressure threshold.4. The device of or claim 2 , further comprising a progenitor cell.5. The device of wherein the progenitor cell is a fibroblast claim 4 , a chondrocyte claim 4 , an osteoblast claim 4 , a skeletal myocyte claim 4 , a cardiac myocyte claim 4 , a mesenchymal progenitor cell claim 4 , a hematopoietic progenitor cell claim 4 , a satellite cell claim 4 , a neural progenitor cell claim 4 , a pancreatic progenitor cell claim 4 , a blast cell or a combination thereof.6. The device of any of the preceding claims wherein the emulsion is a double emulsion comprising a primary emulsion and a secondary emulsion.7. The device of wherein the primary emulsion comprises water-in-PFC claim 6 , and the secondary emulsion comprises water-in-PFC-in-water.8. The device of any of the preceding claims claim 6 , further comprising a surfactant.9. The device of claim ...

Подробнее
Номер записи: 90
12-12-2013 дата публикации

Metal-based thiophene photodynamic compounds and their use

Номер: US20130331367A1
Автор: Sherri Ann McFARLAND
Принадлежит: Individual

Compositions of the invention include tunable metal-based thiophene photodynamic compounds useful as therapeutic agents and as in vivo diagnostic agents for treating or preventing diseases that involve hyperproliferating cell etiology including cancer and diseases associated with hyperproliferating cells. The compositions are also useful for treating infectious diseases and for pathogen disinfection.

Подробнее
Номер записи: 91
12-12-2013 дата публикации

COMPOSITIONS AND METHODS FOR POTENTIATING SONOTHROMBOLYSIS

Номер: US20130331738A1
Автор: BORRELLI MICHAEL
Принадлежит:

Methods and compositions for potentiating the sonothrombolysis of a thrombus within a circulatory vessel of a patient are described. In particular, a method of performing sonothrombolysis in which a suspension that may include microbubbles, degradable starch nanoparticles, and a tissue permeabilizer is administered to the patient in tandem with the directing of ultrasound pulses at the thrombus is described. 1. A composition to enhance the rate of dissolution of a thrombus in a circulatory vessel of a patient using a sonothrombolysis procedure , the composition comprising:(a) an amount of microbubbles;(b) an amount of starch nanoparticles; and(c) an amount of a tissue permeabilizing agent;wherein the composition is in the form of a suspension introduced into the circulatory vessel near the thrombus prior to the sonothrombolysis procedure.2. The composition of claim 1 , wherein the amount of microbubbles has a concentration in the suspension ranging from about 0.1 microbubble/mL to about 5×10microbubbles/mL.3. The composition of claim 1 , wherein each microbubble of the amount of microbubbles has a microbubble diameter ranging from about 0.1 μm to about 10 μm.4. The composition of claim 1 , wherein the amount of starch nanoparticles has a concentration ranging from about 0.01 mg/mL to about 0.1 mg/mL.5. The composition of claim 1 , wherein each starch nanoparticle in the amount of starch nanoparticles has a nanoparticle diameter ranging from about 10 nm to about 500 nm.6. The composition of claim 1 , wherein the tissue permeabilizer is chosen from cyclopentadecanolide claim 1 , cycloundecanone claim 1 , and PLURONIC P85.7. The composition of claim 6 , wherein the amount of tissue permeabilizer has a concentration ranging from about 0.0001% w/V to about 1% w/V.8. The composition of claim 1 , further comprising an amount of tPA.9. The composition of claim 9 , wherein the amount of tPA has a concentration ranging from about 0.0 mg/mL to about 0.2 mg/mL.10. A method of ...

Подробнее
Номер записи: 92
12-12-2013 дата публикации

ANTICANCER AGENT DELIVERY SYSTEM USING pH-SENSITIVE METAL NANOPARTICLES

Номер: US20130331764A9
Автор: Kim Sungjee, Nam Jutaek
Принадлежит:

The present invention relates to a method for effectively delivering an anticancer drug into cancer cells by binding the anticancer drug to pH-sensitive metal nanoparticles so as to be separated from cancer cells. The pH-sensitive metal nanoparticles according to the present invention may be heated by photothermal therapy, thereby effectively killing cancer cells in conjunction with the isolated anticancer drug. 1. A method for delivering an anticancer drug to cells , comprising:conjugating the anticancer drug to a pH-sensitive metal nanoparticle; andreleasing the anticancer agent in an acidic pH condition.3. The method of claim 1 , wherein the anticancer agent has a primary amine group or —OH group.4. The method of claim 3 , wherein the anticancer agent is selected from the group consisting of doxorubicin claim 3 , Methotrexate claim 3 , Paclitaxel claim 3 , Cisplatin claim 3 , Bleomycin and a combination thereof.5. The method of claim 2 , wherein the anticancer drug is conjugated to the compound of Chemical Formula 1 by means of EDC and sulfo-NHS.6. The method of claim 1 , wherein the anticancer drug is released from the metal nanoparticle by hydrolysis.8. The method of claim 1 , wherein the anticancer drug is released in a sustained manner.9. A pH-sensitive metal nanoparticle for therapy of cancer claim 1 , being loaded with an anticancer drug claim 1 , wherein the anticancer drug is released from the metal nanoparticle in an acidic pH condition.11. The pH-sensitive metal nanoparticle of claim 9 , ranging in size from about 5 to 15 nm.12. The pH-sensitive metal nanoparticle of claim 9 , wherein the anticancer drug is released by hydrolysis.13. The pH-sensitive metal nanoparticle of claim 9 , wherein the anticancer drug is selected from the group consisting of doxorubicin claim 9 , Methotrexate claim 9 , Paclitaxel claim 9 , Cisplatin claim 9 , Bleomycin and a combination thereof.18. The pH-sensitive metal nanoparticle of claim 17 , wherein the dye is Alexa Fluor ...

Подробнее
Номер записи: 93
19-12-2013 дата публикации

BIOFUNCTIONALIZED MAGNETIC NANOWIRES

Номер: US20130337034A1
Автор: Contreras Gerenas Maria Fernanda, Kosel Jurgen, Ravasi Timothy
Принадлежит: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY

Magnetic nanowires can be used as an alternative method overcoming the limitations of current cancer treatments that lack specificity and are highly cytotoxic. Nanowires are developed so that they selectively attach to cancer cells via antibodies, potentially destroying them when a magnetic field induces their vibration. This will transmit a mechanical force to the targeted cells, which is expected to induce apoptosis on the cancer cells. 1. A composition comprising:a plurality of nanowires, at least a portion of the plurality of nanowires being responsive to a magnetic field; anda plurality of targeting moieties, each of the moieties having a first affinity for a surface of a predetermined cell type and a second affinity for a nanowire in the plurality of nanowires, wherein at least one moiety in the plurality of targeting moieties is in contact with a nanowire of the plurality of nanowires, wherein the plurality of nanowires responds to a magnetic field.2. The composition of claim 1 , wherein the first affinity includes the targeting moiety configured to have specific recognition and binding to the surface of the predetermined cell type.3. The composition of claim 1 , wherein the second affinity includes the targeting moiety is configured to conjugate to the nanowire through the chemical groups of the moiety with the surface of the nanowire.4. The composition of claim 1 , wherein each of the plurality of nanowires includes nickel claim 1 , cobalt claim 1 , iron claim 1 , or alloys or combinations thereof.5. The composition of claim 1 , wherein each nanowire in the plurality of nanowires includes a gold coating.6. The composition of claim 1 , wherein the targeting moiety is an antibody.7. The composition of claim 6 , wherein the antibody has a first affinity to a membrane receptor of a cancer cell.8. The composition of claim 1 , wherein the moieties are randomly distributed on a nanowire in the plurality of nanowires.9. The composition of claim 1 , wherein the ...

Подробнее
Номер записи: 94
19-12-2013 дата публикации

Composition Used for Thermotherapy and Producing Method Thereof and Method to Treat Cancer

Номер: US20130337043A1
Автор: CHI Kwan-Hwa, LIAO Kuang-Wen, WANG Yu-Shan
Принадлежит:

A composition used for thermotherapy includes a carrier structure and a plurality of metal particles. The carrier structure includes a lipid layer, a positive charged polymer and a surface active polymer. The positive charged polymer and the surface active polymer are dispersed on the lipid layer by non-covalent bonding. The metal particles are encapsulated in the carrier structure. A producing method of the composition used for thermotherapy and a method for using the composition in cancer treatment are also disclosed. 1. A composition used for thermotherapy , comprising:a carrier structure, comprising:a lipid layer,a positive charged polymer dispersed on the lipid layer by non-covalent bonding, anda surface active polymer dispersed on the lipid layer by non-covalent bonding; anda plurality of metal particles encapsulated in the carrier structure.2. The composition of claim 1 , wherein the carrier structure comprises liposome.3. The composition of claim 1 , wherein the carrier structure comprises temperature-sensitive liposome.4. The composition of claim 1 , wherein the ratio of the lipid layer claim 1 , the positive charged polymer and the surface active polymer is between 3:1:1 and 60:1:1.5. The composition of claim 1 , wherein the lipid layer is a neutral lipid layer comprising DLPC claim 1 , DOPC claim 1 , DMPC claim 1 , DPPC claim 1 , DSPC claim 1 , DOPC claim 1 , DMPE claim 1 , DPPE claim 1 , DOPE claim 1 , DMPA claim 1 , DPPA claim 1 , DOPA claim 1 , DMPG claim 1 , DPPG claim 1 , DOPG claim 1 , DMPS claim 1 , DPPS claim 1 , or DOPS.6. The composition of claim 1 , wherein the positive charged polymer comprises polyamine claim 1 , polyethylenimine (PEI) claim 1 , polyvinylpyrrolidone claim 1 , or polyacetic acid.7. The composition of claim 1 , wherein the surface active polymer comprises crosslinked type polyacrylate salt claim 1 , saponin claim 1 , or Polyethylene glycol (PEG).8. The composition of claim 1 , wherein the carrier structure further comprises a ...

Подробнее
Номер записи: 95
19-12-2013 дата публикации

SILICON NANOPARTICLEFOR PHOTODYNAMIC CANCER TREATMENT UTILIZING QUANTUM DOT OPTICAL PROPERTIES

Номер: US20130337069A1
Автор: Beckman James, Ischenko Anatoli
Принадлежит:

Quantum active sized silicon nanoparticles with a silicon core covered by a thin 0.5-1.5 nm oxide/nitride shell are described for light exposure in the 300-600 nm range for transforming atmospheric oxygen to singlet oxygen for causing cell apoptosis as a type of photodynamic cancer therapy. A method of use of the nanoparticle in a non-hydrophobic cream is also taught along with a blocking scheme for controlled reaction of the nanoparticle. 1. A photo-sensibilizing nanoparticle for use with light and oxygen molecules in forming singlet oxygen , the nanoparticle comprising:a silicon core; anda discrete reactant outer shell having a thickness less than 1.5 nanometers, the silicon core and discrete reactant outer shell forming a colloid-free nanoparticle;the reactant outer shell formed from at least one shell reactant selected from the reactant group consisting of oxygen and nitrogen,the combined silicon core and reactant outer shell having a cross section distance of greater than 2 and less than 9 nanometers;wherein exposure of the nanoparticle to the light causes singlet oxygen formation from the oxygen molecules adjacent the exterior surface of the nanoparticle.2. A skin treatment nanoparticle medium for use with light and oxygen molecules , the medium comprising:a non-hydrophobic base carrier; andcolloid free silicon core nanoparticles having a silicon core and an outer shell with a thickness less than 1.5 nanometers, the combined silicon core and outer shell having a cross section distance of greater than 2 and less than 9 nanometers, the shell formed from at least one shell reactant selected from the reactant group consisting of oxygen and nitrogen, the nanoparticle dispersed throughout the non-hyrophobic base carrier to form the nanoparticle medium;wherein exposure of the nanoparticle gel to the light causes singlet oxygen formation from the oxygen molecules. This application claims priority to and is a continuation-in-part of U.S. Utility application Ser. No. 12 ...

Подробнее
Номер записи: 96
19-12-2013 дата публикации

ANTICANCER PRODRUG ACTIVATED BY RADIATION OR ULTRAVIOLET TREATMENT AND USE THEREOF

Номер: US20130338422A1
Автор: Chi Dae-Yoon, Choi Kui-Won, Kil Hee-Seup, Kim Kwang-Meyung, Kim Sang-Yoon, Kwon Ick-Chan, LEE Beom-Suk, Ryu Ju-Hee, Sung Hyun-Ju
Принадлежит: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid or base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy. 1. A prodrug position comprising a peptide having acetyl-SEQ ID NO: 1 , a linker , and an anticancer drug that are sequentially linked to each other , wherein the peptide having acetyl-SEQ ID NO: 1 is cleaved by active caspase.2. The prodrug according to claim 1 , wherein the anticancer drug is released at the radiated region of radioactive ray or UV by the cleavage of the prodrug with active caspase which is activated by radiation or UV treatment.3. The prodrug according to claim 1 , wherein the caspase is caspase-3.4. The prodrug according to claim 1 , wherein the linker is selected from the group consisting of para-aminobenzyloxycarbonyl claim 1 , aminoethyl-N-methylcarbonyl claim 1 , aminobiphenylmethyloxycarbonyl claim 1 , a dendritic linker and a cephalosporin-based linker.5. The prodrug according to claim 1 , wherein the anticancer drug is selected from the group consisting of doxorubicin claim 1 , paclitaxel claim 1 , adriamycin claim 1 , cisplatin claim 1 , 5-fluorouracil claim 1 , mitomycin claim 1 , chlomomycin claim 1 , bleomycin claim 1 , peplomycin claim 1 , daunorubicin claim 1 , aclarrubicin claim 1 , neocarzinostatin claim 1 , epirubicin claim 1 , idarubicin and pirarubicin.6. The prodrug according to claim 1 , wherein the anticancer drug is ...

Подробнее
Номер записи: 97
26-12-2013 дата публикации

GRAPHITE-COATED MAGNETIC NANOPARTICLES

Номер: US20130343996A1
Автор: Lee Ki-Bum, Subramaniam Prasad
Принадлежит: Rutgers, The State University of New Jersey

The present invention relates to graphite-coated magnetic nanoparticles, methods for the synthesis of graphite-coated magnetic nanoparticles, and methods of using graphite-coated magnetic nanoparticles for targeted delivery of siRNA-based therapy, as multimodal imaging probes and for hyperthermia cancer treatment. 1. A nanoparticle comprising an iron cobalt core; a graphitic carbon shell surrounding the core; a biocompatible carbohydrate coating disposed on the shell; a cationic coating disposed on said biocompatible coating; and small interfering RNAs (siRNAs) disposed on said cationic coating , wherein said siRNAs are selected to interfere with expression of a gene in a tumor cell.2. The nanoparticle of claim 1 , wherein said carbohydrate of said biocompatible coating comprises functional groups for covalent attachment of tumor targeting agents; and said nanoparticle further comprises a targeting agent for said tumor cell conjugated to one of said functional groups.3. The nanoparticle of claim 2 , wherein said carbohydrate is dextran.4. The nanoparticle of wherein said targeting agent is an antibody claim 2 , a peptide claim 2 , a carbohydrate claim 2 , a lipopolysaccharide claim 2 , or a small molecule.5. The nanoparticle of claim 4 , wherein said antibody is a monoclonal antibody that binds to an epidermal growth factor receptor.6. The nanoparticle of claim 4 , wherein said targeting agent is a peptide containing a RGD sequence.7. The nanoparticle of claim 1 , wherein said cationic coating comprises polyethyleneimine.8. A pharmaceutical composition comprising the nanoparticle of and a pharmaceutically acceptable carrier.9. A method to deliver a siRNA to the intracellular region of a cell of interest in a subject comprising administering a pharmaceutical composition comprising the nanoparticle of .10. The method of claim 9 , wherein the nanoparticle comprises a targeting agent for an epidermal growth factor receptor or a receptor that specifically binds to a ...

Подробнее
Номер записи: 98
09-01-2014 дата публикации

Hypoxia-Targeted Polymeric Micelles For Cancer Therapy And Imaging

Номер: US20140010760A1
Автор: Dagli Dinesh J., Giri Anshu, Giri Brij P., Gregg Kristina, Singh Pritam
Принадлежит:

The present invention provides a composition and method for targeting hypoxic tumor areas for detection or treatment or a treatment adjuvant for cancer. Specifically, a hypoxia targeting moiety is conjugated to a polymeric micelle containing imaging agents, therapeutic agents, or therapeutic adjuvants. 2. The micelle of wherein:the polymeric micelle has a size ranging from about 10 nm to about 100 nm in diameter and comprises a hydrophobic biocompatible core and a hydrophilic or polar biocompatible corona.3. The micelle of wherein:the biocompatible polymer forming the core of the PMC is selected from the group consisting of polystyrene, poly(divinylbenzene), poly(acrylate), polymethylmethacrylate, poly(hydroxyethyl methacrylate), poly(vinyltoluene), poly(butadiene), poly(aspartic acid), poly(benzyl aspartate), polycaprolactone and derivatives thereof, poly(lactide) and derivatives thereof, poly(benzyl glutamate), poly(L-lysine), poly(propylene oxide), oligo(methyl methacrylate), poly(isoprene), poly(isopropyl acrylamide), calixarenes, polyanhydrides, pseudo-poly(amino acids), polyphosphazenes and derivatives thereof and mixtures thereof.4. The micelle of wherein:The corona forming biocompatible polymer is selected from the group consisting of, poly(ethylene glycol), poly(vinyl alcohol), poly(acrylic acid), poly(methacrylic acid), poly(acrylamide), poly(vinyl pyrrolidone), poly(ethylene oxide), poly(propylene oxide), poly(vinylmethyl ether), hydroxypropyl cellulose, chitosans, polysaccharides, tertiary ammonium and phosphonium salts, and mixtures thereof.6. The micelle of wherein:the hypoxia targeting moiety is selected from the group consisting of aromatic N-oxide, aliphatic N-oxide, nitroazole, nitroimidazole, nitrothiophene, nitrothiazole, nitrooxazole, nitrofuran, nitropyrrole, transition metal moieties, and mixtures thereof.7. The micelle of wherein:the imaging or contrast agent is selected from the group consisting of fluorophores, dyes, quantum dots, ...

Подробнее
Номер записи: 99
09-01-2014 дата публикации

Targeted hollow gold nanostructures and methods of use

Номер: US20140012224A1
Автор: Olson Tammy Y., Schwartzberg Adam, Zhang Jin Z.
Принадлежит: The Regents of the University of California

Provided are novel nanostructures comprising hollow nanospheres (HGNs) and nanotubes for use as chemical sensors, molecular specific photothermal coupling agents, and photothermal ablation compounds. The nanostructures can be used in electromagnetic radiation-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are of particular use in the fields of clinical diagnosis, clinical therapy, clinical treatment, and clinical evaluation of various diseases and disorders, manufacture of compositions for use in the treatment of various diseases and disorders, for use in molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof. The hollow gold nanospheres have a unique combination of spherical shape, small size, and strong, tunable, and narrow surface plasmon resonance absorption covering the entire visible to near IR region. 1. A photothermal ablation composition comprising a plurality of isolated substantially homogenous polycrystalline uniform symmetrical hollow metal nanoshells or nanospheres , the isolated substantially homogenous polycrystalline uniform symmetrical hollow metal nanospheres or nanoshells comprising a targeting molecule , wherein at least one of the isolated substantially homogenous polycrystalline uniform symmetrical hollow metal nanoshells or nanospheres comprises a wall , the wall further comprising an exterior wall surface , wherein the targeting molecule is bound to the exterior wall surface , the isolated substantially homogenous polycrystalline uniform symmetrical hollow metal nanoshells or nanospheres having a size of between about 20 nm and about 100 nm in diameter , and wherein the wall further comprises an interior wall surface diameter and an exterior wall surface diameter thereby defining the wall thickness , and wherein the wall thickness ...

Подробнее
Номер записи: 100